

Complete Specifications Accepted

Copies of the specification and drawings (if any) can be obtained from the IPONZ website www.iponz.govt.nz.

At any time within 3 months from the date of issue of this *Journal*, any person interested may give notice of opposition to the grant of a patent on any of the applications relating to the accepted complete specification shown hereunder, by filing form 15 in duplicate accompanied by a statement of the case in duplicate and a fee of \$300 plus GST where applicable, provided that if an application for extension on form 16 is made within the said 3 months, the Commissioner may extend the prescribed period for opposition to 4 months from the date of issue of this *Journal*. The grounds for giving notice of opposition are specified in section 21 of the Act, and prospective opponents should also refer to regulations 48 to 56 of the Patents Regulations 1954.

(21) 536005 (22) 30 Apr 2003

(54) Water desalinization process and apparatus using solar heating, condensation and the Venturi effect

(86) PCT/US2003/013712 (87) WO2003/092847

(51) IPC2010.01:B01D1/00; B01D3/02; C02F1/04,14; B01D5/00

(71) Desal, LLC


(72) Ciudad, Jeffrey;

(31) 02 377769 (32) 2 May 2002

(33) US

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) A process and device (1) for desalinizing water is disclosed. The process comprises of providing a blackened surface (16) in contact with a body of water (31) so as to heat air and evaporate the water from the blackened surface (16). The heated air and water vapour is channelled upward, through a vertical Venturi wind shaft (10), creating an adiabatic pressure variance. The heated air and water vapour are then released into a first chamber (6) of a series of interconnected chambers (5). The water vapour condenses (23) within the chambers (5) and drains to a series of basins (26) at the bottom of the chambers (5) which in turn drain to a reservoir (36). The heat from the air in the upper zone (17) of the chambers (5) is absorbed by a heat transfer duct (40) containing cool air collected off the body of water (31). The heated air in the duct (40) is then expelled out of the top of the structure along with the air that the water was extracted from by way of the air exhaust port (48).



(21) 537833 (22) 18 Jul 2003

(54) Compositions and methods for VEGF siRNA inhibition of angiogenesis

(86) PCT/US2003/022444 (87) WO2004/009769

(51) IPC2010.01:C12N15/11; C12Q1/68; C07H21/02; C12N15/85,86

(71) The Trustees of the University of Pennsylvania


(72) Tolentino, Michael J; Reich, Samuel Jotham;

(31) 02 398417 (32) 24 Jul 2002 (33) US

(31) 02 294228 (32) 14 Nov 2002 (33) US

(74) Mallesons Stephen Jaques, Level 50 Bourke Place, 600 Bourke Street, Melbourne, VIC 3000, Australia

(57) Disclosed is an isolated siRNA comprising a sense RNA strand and an antisense RNA strand, wherein the sense and an antisense RNA strands form an RNA duplex, and wherein the sense RNA strand comprises a nucleotide sequence identical to a target sequence of about 19 to about 25 contiguous nucleotides in human VEGF mRNA. The siRNA are useful for treating diseases or conditions involving angiogenesis.



(21) 540700 (22) 19 Nov 2003

(54) Curtain system comprising several flat panels wherein the panels can be easily removed

(86) PCT/CH2003/000764 (87) WO2004/048738

(51) IPC2010.01:E06B9/36,388


(71) Christopher John Talbot; Susan Jane Talbot

(72) Janach, Walter E;

(31) 02 1976 (32) 25 Nov 2002 (33) CH

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) A curtain system comprising several flat panels (9) made of curtain fabric or other planar material is disclosed. The top of each panel is provided with a horizontal metal, wood, or plastic slat (1) on which the panels (9) hang in a loose manner. Both ends (2, 3) of the slat (1) comprise fastening means (4) for rollers (5) or sliders (6). The rollers (5) or sliders (6) of one end (2) of each slat (1) are guided inside a first common track (7) while the rollers (5) or sliders (6) located at the other end of each slat (1) are guided inside a second common track (8) such that the panels (9) can be slid on top of each other. The panels (9) extend at an acute angle relative to the tracks (7, 8) and can be slid on top of each other until the panels (9) nearly overlap.



(21) 541284 (22) 2 Feb 2004

(54) A wind energy plant where in the electrical equipment resides inside a sealed housing, inside the pylon

(86) PCT/EP2004/000918 (87) WO2004/067959

(51) IPC2010.01:F03D11/00,04; H01F27/06,02; E04H12/00; F03D1/00

(71) Aloys Wobben

(72) Wobben, Aloys;

(31) 03 0304026 (32) 1 Feb 2003 (33) DE


(31) 03 0310036 (32) 6 Mar 2003 (33) DE

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) A wind power installation is disclosed. The installation is characterised in that the power transformation and control equipment (7) is housed inside a water-tight container (10), within the walls of the pylon (9). Means for controlling the atmospheric conditions (11, 12) are described as well

as layout and advantages for work crew. The container is connected to the foundation of the pylon and may be installed on the foundation before the pylon or installed in to the pylon before delivery to the site.

Divisional filed as 586660



(21) 543384 (22) 4 May 2004

(54) Method for selective carbohydrate oxidation using supported gold catalysts

(86) PCT/EP2004/004703 (87) WO2004/099114

(51) IPC2010.01:C07C59/105; C07H7/027; C07C51/235

(71) Sudzucker Aktiengesellschaft Mannheim/Ochsenfurt

(72) Kowalczyk, Jorg; Begli, Alireza Haji; Prusse, Ulf; Berndt, Heinz; Pitsch, Irene;

(31) 03 0319917 (32) 5 May 2003 (33) DE

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, Victoria 3000, Australia

(57) Disclosed is a method for the selective oxidation of at least one carbohydrate, a carbohydrate mixture or a composition having a content thereof, where an aqueous solution of the carbohydrate, of the mixture or of the composition is reacted in the presence of a gold catalyst comprising nanodispersed gold particles on a metal oxide support (such as titanium dioxide TiO₂ or aluminium oxide Al₂O₃), and of oxygen, where an aldehyde group on the C1 carbon atom of the carbohydrate(s) is selectively oxidized to a carboxyl group, or an aldehyde group is introduced on the C1 carbon atom and selectively oxidized to a carboxyl group.

Divisional filed as 585754

(21) 545343 (22) 17 Sep 2004

(54) Pharmaceutical products comprising bisphosphonates

(86) PCT/EP2004/010470 (87) WO2005/025551

(51) IPC2010.01:A61K47/26,12; A61K31/663,4164

(71) Novartis AG

(72) Glausch, Alexandra; Loffler, Rolf; Sigg, Juergen;

(31) 03 504402 (32) 18 Sep 2003 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a pharmaceutical product in the form of a ready to use solution comprising a container containing a solution of zoledronic acid or a pharmaceutically acceptable salt thereof, in which at least the internal surface of the container comprises a plastic material wherein such plastic material is a cycloolefinic polymer and in which the filled container is heat sterilised and wherein the product is in unit dose form having a volume of 100 ml.

(21) 545452 (22) 12 Sep 2005

(54) Hot air heater with heating wires arranged cancel out the electromagnetic field produced by the wires

(86) PCT/JP2005/016715 (87) WO2006/030726

(51) IPC2010.01:F24H3/04; A45D20/10; H05B3/16; A45D20/30

(71) BAN-YU CO., LTD.; OSAKA PREFECTURAL GOVERNMENT


(72) Ono, Yoshio; Hirohata, Takeshi;

(31) 04 267008 (32) 14 Sep 2004 (33) JP

(31) 05 130877 (32) 28 Apr 2005 (33) JP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a hot air heater which includes a number of heating wires wound around an insulating fire-resistant substrate. The heating wires are connected in parallel or in series between an input line and an output line of an electric power supply. The heating wires are wound around the insulating fire-resistant substrate in such a manner that current runs in opposite directions through the heating wires so as to cancel out electromagnetic waves generated from the heating wires.



(21) 546370 (22) 8 Oct 2004

(54) Beer additive and method

(86) PCT/AU2004/001392 (87) WO2005/033259

(51) IPC2010.01:C12C5/02; C12C12/04

(71) Belair Biotechnology Pty Ltd

(72) Kaehne, Ian David;

(74) A.P.T. PATENT AND TRADE MARK ATTORNEYS, 383 Goodwood Road, Westbourne Park, SA 5041, Australia

(57) Disclosed is a method of enhancing the taste of a beer with a mineral additive, comprising the step of adding the mineral additive to the beer, the mineral additive including soluble compounds of minerals in ranges of final concentrations of the respective element in the finished beer, to enhance taste characteristics of the diluted beer when compared to a dilution solely with water as per the specification, wherein the pH adjusted by the addition of phosphoric acid such that pH of the finished beer is in the range of about 3.5 to about 5.0. Also disclosed is the beer made from the method, a concentrate made by the method and a kit employing the method.

(21) 547633 (22) 5 Nov 2004

(54) Monomethylvaline compounds capable of conjugation to ligands

(86) PCT/US2004/038392 (87) WO2005/081711

(51) IPC2010.01:A61P35/00; C07D207/09,08

(71) Seattle Genetics Inc

(72) Doronina, Svetlana O; Senter, Peter D; Toki, Brian E; Ebens, Allen J; Kline, Toni Beth; Polakis, Paul; Sliwowski, Mark X; Spencer, Susan D;

(31) 03 518534 (32) 6 Nov 2003 (33) US

(31) 04 557116 (32) 26 Mar 2004 (33) US

(31) 04 598899 (32) 4 Aug 2004 (33) US


(31) 04 622455 (32) 27 Oct 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound having the formula DF or a conjugate thereof, wherein the wavy line of DF indicates H or a covalent attachment site to a Linker Unit or a Ligand Unit selected from the group consisting of a protein, a polypeptide and a peptide and the rest of the substituents are disclosed within the specification.

Also disclosed is the use of the conjugate having the formula DF in the manufacture of a medicament to treat a cancer or a medicament to treat an autoimmune disease or a medicament to treat an infectious disease.

Divisional filed as 583292



(21) 547857 (22) 10 Feb 2005

(54) Session-by-session adjustment of a device for treating sleep disordered breathing

(86) PCT/AU2005/000174 (87) WO2005/077447

(51) IPC2010.01:A61M16/00

(71) ResMed Limited


(72) Farrugia, Steven Paul;

(31) 04 543491 (32) 11 Feb 2004 (33) US

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) A system for treating sleep disordered breathing (SOB) during successive treatment sessions is disclosed. The system provides continuous positive airway pressure during sleep. The system includes a blower, a blower controller, a mask for communicating pressurized air between the blower and a patient, and a mechanism for allowing the controller to derive signals indicative of pressure and flow. The controller controls a constant treatment pressure applied during a first session. The controller then derives a sleep disorder index (SOI) representative of the number of SOB episodes that occurred during the first session, and based on the SOI, determines if an adjustment in treatment pressure is required. The controller then controls an adjustment in the treatment pressure during a second, subsequent session if it was determined that an adjustment is required. The first and second sessions are separate in that the blower is turned off between the sessions.

Divisional filed as 581725



(21) 547916 (22) 3 Jan 2005

(54) Process of microstructuring of a surface of a multi-layered flexible substrate, and microstructured substrate

(86) PCT/BE2005/000001 (87) WO2005/063464

(51) IPC2010.01:B29C35/08; B29C59/02; B29D11/00; C09J7/02; B32B31/00

(71) MACtac Europe S.A

(72) Stocq, Robert Ghislain;


(31) 03 03079017 (32) 29 Dec 2003 (33) EP

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) Method of forming a three-dimensional microstructure on a surface, uses thereof, and microstructured products so obtained A method of forming a three-dimensional microstructure on a flat surface of a support, comprising the application of a first flat and uniform layer of silicone on said surface of support and the application on the first layer of silicone of a second three dimensionally microstructured layer of silicone, said first layer and second layer of silicone become integrally connected to thus form a common three-dimensional microstructure ensuring anti-adhe-

sive properties distributed regularly on the surface of the support, so that any flexible surface of substrate, in particular a surface of adhesive deposited on said layers of silicone will be microstructured by inverse replication of the three-dimensional microstructure formed by the two layers of silicone,; where said layers of silicone are fixed by hardening by heating or by exposure to an ultraviolet or electronic radiation, or a combination thereof, applications thereof and films, notably self-adhesive films, such as those microstructured by said method.

Divisional filed as 584826



(21) 548074 (22) 21 Dec 2004

(54) Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment

(86) PCT/US2004/043112 (87) WO2005/063744

(51) IPC2010.01:A61K31/437; C07D471/04

(71) GERHARD PUERSTINGER; GILEAD SCIENCES, INC.; K.U. LEUVEN RESEARCH & DEVELOPMENT

(72) Bondy, Steven S; Dowdy, Eric Davis; Kim, Choung U; Oare, David A; Neyts, Johan; Zia, Vahid; Puerstinger, Gerhard;

(31) 03 532292 (32) 22 Dec 2003 (33) US

(31) 04 591069 (32) 26 Jul 2004 (33) US

(31) 04 590990 (32) 26 Jul 2004 (33) US

(31) 04 591024 (32) 26 Jul 2004 (33) US


(31) 04 590989 (32) 26 Jul 2004 (33) US

(31) 04 533963 (32) 2 Jan 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of the pictured formula, wherein R1 and R3 are substituted rings as defined in the specification, and wherein the other substituents are also defined in the specification. Also disclosed is the use of the compound to treat viral infections such as the hepatitis-C virus.

Divisional filed as 583756



(21) 548193 (22) 7 Jan 2005

(54) Adjustable length breathing circuit

(86) PCT/US2005/000402 (87) WO2005/070063

(51) IPC2010.01:A61M15/00; A62B7/00; A62B9/00

(71) KING SYSTEMS CORPORATION

(72) Burrow, Kevin D; Irlbeck, Dennis; Mcgrail, Thomas W; Burrow, Bart H; Mitchell, Michael G; Richards, David L;


(31) 04 535235 (32) 9 Jan 2004 (33) US

(31) 04 811121 (32) 26 Jun 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A unilimb breathing circuit is disclosed. The unilimb breathing circuit comprises a corrugated expiratory and inspiratory tube, a proximal end coupling member, and a distal end coupling member. The expiratory and inspiratory tubes have first and second ends, and are expandable between a fully compressed rest position and a fully expanded rest position. The tubes have a plurality of intermediate rest positions and are capable of maintaining their rest length without the exertion of an external force. In the assembled breathing circuit, the first end of the expiratory and inspiratory tubes are coupled to the proximal end coupling member, and the second end of the expiratory and inspiratory tubes are coupled to the distal end coupling member. The assembled breathing circuit is configured such that when the expiratory tube is in the fully expanded rest position, the inspiratory tube is in an intermediate rest position.

Divisional filed as 587031



(21) 548207 (22) 21 Jan 2005

(54) Implantable device fastening system and methods of use

(86) PCT/US2005/001958 (87) WO2005/072627

(51) IPC2010.01:A61B17/04

(71) Allergan Sales, LLC

(72) Birk, Janel; Coe, Frederick L; Hoyt, Robert E;

(31) 04 538674 (32) 23 Jan 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A system for implanting an injection port includes the implantable injection port 10, a deployment tool that includes a distal cover 21 defining a recess to receive the injection port, and a protective fixture to removably attach over the lower face of the injection port to cover the injection port fasteners so as to prevent contact with a user.

The injection port includes a housing, a septum penetrable by a needle is retained by the housing and forms part of the upper face of the port, a fluid reservoir below the septum, an outlet conduit extending through the housing from the reservoir, and a plurality of sharp fasteners 14 which enable an installer to attach the port to tissue. The fasteners can be moved from an undeployed position to a deployed position in which they extend below the lower face of the port.

The deployment tool includes a proximal handle that extends upwardly from the distal cover to a manual actuator and a transmission 22, 24 that extends along the handle to transmit movement of the actuator to simultaneously move the fasteners 14 from the undeployed to the deployed position

Divisional filed as 586427



(21) 548393 (22) 7 Jan 2005

(54) Nanoparticles comprising a fluorescent dye based on entrapment of a protein or DNA dye as agents for imaging finger prints

(86) PCT/GB2005/000038 (87) WO2005/066632

(51) IPC2010.01:G01N33/533,58,92

(71) UNIVERSITY OF SUNDERLAND

(72) Rowell, Frederick John; Theaker, Brenden John;

(31) 04 0400235 (32) 7 Jan 2004 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Discloses an agent for imaging latent fingerprints comprising nanoparticles, wherein said nanoparticles comprises an intrinsic fluorescent material or a fluorescent dye selected from a protein-dye conjugate and a DNA-dye conjugate, wherein said fluorescent material or fluorescent dye is entrapped within the nanoparticle and wherein said nanoparticles are derived from a sol gel. Particularly preferred embodiments utilise cadmium sulphide or cadmium selenide nanoparticles, Texas Red labelled gelatin, porcine thyroglobulin or fluorescein-labelled bovine serum albumin. Further disclosed are methods of detecting latent fingerprints comprising the use of said nanoparticles.

(21) 548479 (22) 16 Dec 2004

(54) Shock-absorbing system for fastener driving tools using deformable members

(86) PCT/US2004/042297 (87) WO2005/082580

(51) IPC2010.01:B25C1/08; F16F1/08; F16F7/12


(71) Illinois Tool Works Inc.

(72) Shkolnikov, Yury; Taylor, Walter J;

(31) 04 774269 (32) 6 Feb 2004 (33) US


(74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, Victoria, Australia

(57) Disclosed is a combustion chamber assembly (10) for use in a combustion-powered fastener driving tool. The chamber assembly includes a cylinder body (18); a reciprocating probe assembly (26) slidably mounted to said cylinder body between a first, extended position and a second, retracted position; at least one shock-absorbing member (56), operationally associated with at least one of the cylinder body and the probe assembly for reducing shock load generated during operation of the tool. The probe assembly includes an upper probe including at least one arm portion (42) in sliding relationship relative to the cylinder body and having an upper end (44). The shock-absorbing member is disposed between the upper end and a corresponding element of the cylinder body for transmitting loads from the probe assembly to the cylinder body. The shock absorbing member is also configured to reduce load forces generated in a combustion chamber of the chamber assembly upon the probe assembly reaching the second position. The shock absorbing member is further configured and to be rigid enough to limit travel of the probe assembly relative to the cylinder body, and have sufficient resilience to absorb shock forces generated by the tool in said second position.




(21) 548529 (22) 16 Dec 2004
 (54) Pegylated small molecules
 (86) PCT/US2004/042661 (87) WO2005/058367
 (51) IPC2010.01:A61K47/48; C08G65/08
 (71) NEKTAR THERAPEUTICS
 (72) Bentley, Michael D; Viegas, Tacey X; Goodin, Richard R; Cheng, Lin; Zhao, Xuan;
 (31) 03 530122 (32) 16 Dec 2003 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is a conjugate of naloxol with an ethylene glycol oligomer, 6-CH₃-(OCH₂CH₂)₇-O-naloxol, and pharmaceutically acceptable salts and isomers thereof.
 Divisional filed as 583573


(21) 548634 (22) 11 Feb 2005
 (54) Tree stump grinder having teeth which include a slot in the tooth body that engages a slot in a rotor of a grinding wheel of the tree stump grinder
 (86) PCT/EP2005/050609 (87) WO2005/077151
 (51) IPC2010.01:A01G23/06; B02C18/08,14,18
 (71) MULTI-TIP DESIGNS LIMITED
 (72) Watts, Patrick;
 (31) 04 04250748 (32) 11 Feb 2004 (33) EP
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) A tooth for use in a grinding wheel having a rotor, and a grinding unit that uses the tooth, is disclosed. The tooth comprises a main body where the body has a slot defined by two substantially planar surfaces for, in use, engaging with a slot in the rotor. The cutting face includes at least two tips which are perpendicular to each other. At least one cutting face is connected to, and extends away from, the main body. In use, the force in the plane of the rotor is transferred onto the rotor via one of the planar surfaces provided on the slot.



(21) 548885 (22) 31 Jan 2005
 (54) Cylindrical microwave chamber with waveguides
 (86) PCT/US2005/002767 (87) WO2005/079117
 (51) IPC2010.01:C23C14/00; C23C16/00; H01L21/469; H05B31/26; H05B6/70,72,74
 (71) INDUSTRIAL MICROWAVE SYSTEMS, L.L.C.
 (72) Drozd, Michael J; Drozd, Esther;
 (31) 04 521003 (32) 3 Feb 2004 (33) US
 (74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, Victoria 3000, Australia
 (57) A microwave oven comprises a hollow cylinder with longitudinal slots 20 in the wall and an end plate. The end plate closes off one end of the cylinder so that a cylindrical chamber is formed. A waveguide 24 is placed on the outside of the cylinder with the opening of the waveguide lying over a slot 20. The waveguide 24 has spaced apart parallel bars across its opening. The waveguide 24 beams microwaves into the chamber through the slot 20.



(21) 548901 (22) 12 Feb 2005
 (54) 8-[3-Amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
 (86) PCT/EP2005/001427 (87) WO2005/085246
 (51) IPC2010.01:C07D473/04; A61K31/437; A61P3/10
 (71) Boehringer Ingelheim International GmbH
 (72) Himmelsbach, Frank; Langkopf, Elke; Eckhardt, Matthias; Tadayyon, Mohammad; Thomas, Leo;
 (31) 04 008112 (32) 18 Feb 2004 (33) DE
 (31) 04 012921 (32) 17 Mar 2004 (33) DE
 (31) 04 032263 (32) 3 Jul 2004 (33) DE
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed is a 3-[amino-piperidin-1-yl]-xanthine of general formula (I), wherein R is defined in the specification or a tautomer, enantiomer, diastereomer, a mixture or a salt thereof. Also disclosed is a composition comprising said xanthine, the use of said xanthine for preparing pharmaceutical composition for treating type 1 and 2 diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin induced osteoporosis, a process to prepare a composition comprising said xanthine and a process to prepare said xanthine.
 Divisional filed as 587220



(21) 548941 (22) 31 Jan 2005

(54) Stacking implants for spinal fusion

(86) PCT/US2005/002756 (87) WO2005/074850

(51) IPC2010.01:A61F2/28,30,44

(71) OSTEOTECH, INC.

(72) Knaack, David; Winterbottom, John; Belaney, Ryan; Boyce, Todd; Shimp, Lawrence; Lee, Samuel; Kaes, David; Burel, Marc;

(31) 04 540375 (32) 30 Jan 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a system for inducing fusion of vertebrae, comprising: a plurality of stacking inserts for placement in an intervertebral space, each insert comprising a composite consisting essentially of bone fragments embedded in a biocompatible polymer, the composite having osteogenic properties,

wherein a subset of said plurality of stacking inserts may be selected to fit the dimensions of the intervertebral space.

Also disclosed is the use of a composite consisting essentially of bone fragments embedded in a biocompatible polymer, the composite having osteogenic properties, in the manufacture of a plurality of stackable inserts for fusing adjacent vertebrae, wherein the plurality of inserts, when inserted into an intervertebral space, together match the size and shape of the intervertebral space.

(21) 548962 (22) 11 Feb 2005

(54) Melt Extruded Multiparticulates for the Controlled Release of an Active Ingredient

(86) PCT/GB2005/050014 (87) WO2005/079760

(51) IPC2010.01:A61K9/16

(71) Euro-Celtique S.A.

(72) Hayes, Geoffrey Gerard; Danagher, Helen Kathleen; Mohammad, Hassan; Prater, Derek Allan; Tamber, Harjit; Walden, Malcolm; Whitelock, Steve;

(31) 04 03100 (32) 12 Feb 2004 (33) GB

(31) 05 01638 (32) 28 Jan 2005 (33) GB

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) Disclosed is a controlled release pharmaceutical formulation including melt extruded multiparticulates, wherein said multiparticulates include a rubbery matrix including a neutral poly(ethyl acrylate, methyl methacrylate) copolymer and an active agent.

(21) 549009 (22) 18 Feb 2005

(54) 6-substituted 2,3,4,5-tetrahydro-1H-benzo[D]azepines as 5-HT_{2C} receptor agonists

(86) PCT/US2005/005418 (87) WO2005/082859

(51) IPC2010.01:C07D223/16; C07D401/12; C07D403/06,12; C07D405/12; C07D409/12; C07D413/12,14; C07D417/06,12

(71) ELI LILLY AND COMPANY

(72) Allen, John Gordon; Briner, Karin; Cohen, Michael Philip; Galka, Christopher Stanley; Hellman, Sarah Lynne; Martinez-Grau, Maria Angeles; Reinhard, Matthew Robert; Rodriguez, Michael John; Rothhaar, Roger Ryan; Tidwell, Michael Wade; Victor, Frantz; Williams, Andrew Caerwyn; Zhang, Deyi; Boyd, Steven Armen; Conway, Richard Gerard; Deo, Arundhati S; Lee, Wai-Man; Siedem, Christopher Stephen; Singh, Ajay; Mazanetz, Michael Philip;


(31) 04 547681 (32) 25 Feb 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a benzazepine compound of formula I wherein the substituents are disclosed within the specification.

Also disclosed is the use of a compound of formula I for the manufacture of a medicament for the treatment of obesity, an obsessive/compulsive disorder, depression or anxiety.

Divisional filed as 586553



(21) 549049 (22) 12 Jan 2005

(54) Cleaning composition for disposable cleaning head

(86) PCT/US2005/000869 (87) WO2005/072497

(51) IPC2010.01:A47L13/17; B08B7/00; C11D1/83; C11D7/08

(71) THE CLOROX COMPANY

(72) Kilkenny, Andrew; El-Sayed, Maha Y; Foland, Lafayette D; Nelson, Shona L; Scheuing, David R; Rodriguez, Cheryl;

(31) 04 758722 (32) 16 Jan 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a cleaning implement comprising:

a handle and a gripping mechanism, for engagement to a removable cleaning pad;

wherein the removable cleaning pad has a rigid fitment for attaching to the gripping mechanism, and wherein the removable cleaning pad comprises: a nonwoven web substrate; and a cleaning composition impregnated in said substrate;

wherein said cleaning composition comprises: an alkyl sulphate surfactant; and 10-45% sulfamic acid; and wherein the composition has a pH of 2.2 or less. Also disclosed is a cleaning pad comprising a nonwoven web substrate; a cleaning composition impregnated in said substrate;

wherein said cleaning composition comprises: and alkyl sulphate surfactant; and 10 to 65 % of sulfamic acid wherein the composition has a pH of 2.2 or less; wherein the cleaning pad additionally comprises a rigid fitment, wherein the fitment is attached to the substrate.

(21) 549067 (22) 13 Jan 2005

(54) A hand truck having a movable subframe

(86) PCT/AU2005/000028 (87) WO2005/068273

(51) IPC2010.01:B62B1/04; B62B5/02,04; B66F3/00,25; B66F9/08


(71) Anthony Renfrew White

(72) White, Anthony Renfrew;




(31) 04 900194 (32) 16 Jan 2004 (33) AU

(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, Australia



(57) A hand truck for transporting a load is disclosed. The hand truck includes a subframe with a foot portion extending therefrom, so that the sub-frame is able to support the load. A main frame is engaged with the sub-frame so that the sub-frame is able to be extended and retracted with respect to a lower end of the main frame. At least one wheel is secured relative to the main frame so that the truck is able to be wheeled about. A motor, a controller coupled to the motor for enabling a user to control the operation of the motor, and a flexible linkage couples the motor, main frame, and sub-frame together. The motor is operable to move the linkage to thereby extend or retract the sub-frame.




- (21) 549079 (22) 18 Feb 2005
 (54) Viral polymerase inhibitors
 (86) PCT/CA2005/000208 (87) WO2005/080388
 (51) IPC2010.01:C07D401/14; C07D403/12,14; C07D405/14; C07D409/14; C07D413/14; C07D417/14; C07D487/04; C07D235/04; A61P31/14
 (71) BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 (72) Tsantrizos, Youla S; Chabot, Catherine; Beaulieu, Pierre L; Brochu, Christian; Poirier, Martin; Stammers, Timothy A; Thavonekham, Bounkham; Rancourt, Jean;
 (31) 04 546213 (32) 20 Feb 2004 (33) US
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed are benzimidazole compounds of formula (I) wherein R3 is a cycloalkyl; R8 is (C1-6 alkyl; R2 is selected from optionally substituted aryl and Het and wherein the rest of the substituents are disclosed within the specification.
 Also disclosed are similar benzimidazole compounds as disclosed within the specification.
 Also disclosed is the use of the above compounds in the manufacture of a medicament for a HCV infection.
 Divisional filed as 587180



- (21) 549210 (22) 16 Feb 2005
 (54) Packaging for disposable soft contact lenses
 (86) PCT/IB2005/000388 (87) WO2005/082721
 (51) IPC2010.01:A47F1/00; A61F9/00; B65D81/05; B65D75/58; B65D83/00,04; B65D75/32; A45C11/00
 (71) Clearlab Ptd Ltd
 (72) Newman, Stephen D;
 (31) 04 781321 (32) 17 Feb 2004 (33) US
 (31) 04 789961 (32) 27 Feb 2004 (33) US
 (74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Australia
 (57) A contact lens package includes a first space defined by a non-transmissive barrier layer 14, 15, 169 containing a hydration medium and in which the contact lens 4 is disposed. A maximum distance between the non-transmissive barrier layer within the first space is less than the natural sagittal depth of the contact lens so that the package deforms the lens. Such packages take up less space and can be packed within a smaller volume and provide for holding of the lens in a predetermined orientation with respect to the package.



- (21) 549219 (22) 3 Mar 2005
 (54) Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
 (86) PCT/JP2005/004152 (87) WO2005/085265
 (51) IPC2010.01:A61K31/7042; A61P19/06; A61P3/04,06,10; A61P7/10; A61P9/10,12; C07H17/00; C07H7/06
 (71) Kissei Pharmaceutical Co., Ltd.
 (72) Fushimi, Nobuhiko; Fujikura, Hideki; Isaji, Masayuki;
 (31) 04 61429 (32) 4 Mar 2004 (33) JP
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) Disclosed are nitrogenous fused-ring derivatives represented by general formula (I) or pharmacologically acceptable salts thereof, wherein the substituents are disclosed within the specification. Also disclosed is the human SGLT inhibitory activity of the compounds of general formula (I). Accordingly, compounds of the present invention are useful as preventive or therapeutic agents for diseases attributable to hyperglycemia, such as diabetes, postprandial hyperglycemia, impaired glucose tolerance, complications of diabetes, and obesity.



- (21) 549262 (22) 17 Mar 2005
 (54) Catalyst composition comprising shuttling agent for higher olefin multi-block copolymer formation
 (86) PCT/US2005/008915 (87) WO2005/090426
 (51) IPC2010.01:C08F2/38; C08F210/16; C08F297/08
 (71) DOW GLOBAL TECHNOLOGIES INC.

(72) Arriola, Daniel J; Carnahan, Edmund M; Devore, David D; Hustad, Phillip D; Kuhlman, Roger L; Wenzel, Timothy T;

(31) 04 553906 (32) 17 Mar 2004 (33) US


(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a multi-block copolymer formed by polymerizing propylene, 4-methyl-1-pentene, styrene, or another C4-20 alpha-olefin, and a copolymerizable comonomer in the presence of a composition comprising the admixture or reaction product resulting from combining:

a first olefin polymerization catalyst (A),

a second olefin polymerization catalyst (B) capable of preparing polymers differing in chemical or physical properties from the polymer prepared by catalyst (A) under equivalent polymerization conditions, and

a chain shuttling agent (C), wherein catalyst (A) corresponds to one of the two pictured formulas, wherein the metals and substituents are defined herein.



(21) 549330 (22) 10 May 2005

(54) 2H or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof

(86) PCT/FR2005/001154 (87) WO2005/121099

(51) IPC2010.01:C07D231/54,56; A61P25/00; A61K31/416


(71) SANOFI-AVENTIS

(72) Dubois, Laurent; Evanno, Yannick; Maloizel, Christian; Sevrin, Mireille;

(31) 04 0405055 (32) 11 May 2004 (33) FR

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed are benzo[e]indazol-1-yl carbamate derivatives as represented by the general formula (I) in which W represents an oxygen or sulphur atom; R1 and R2 each represent, independently of one another, an aryl, benzyl or alkyl group; or else R1 and R2 form, with the nitrogen atom which carries them, a heterocycle optionally substituted by one or more alkyl or benzyl groups; and wherein the other substituents are as defined herein; in the form of the base or of an addition salt with an acid, and in the hydrate or solvate form. Also disclosed is the use of a compound as defined above for the preparation of a medicament intended to prevent or treat a pathology in which peripheral-type benzodiazepine receptors are involved (conditions such as peripheral neuropathies, motor neuron conditions, neurodegenerative diseases of the central nervous system, anxiety, epilepsy, sleep disorders, acute or chronic renal insufficiency, glomerulonephritis, diabetic nephropathy, cardiac ischaemia and cardiac insufficiency, myocardial infarction, ischaemia of the lower limbs, coronary vasospasm, angina pectoris, pathologies associated with the heart valves, inflammatory heart diseases, side effects due to cardiotoxic medicaments or as a result of heart surgery, atherosclerosis and its thromboembolic complications, restenosis, graft rejections, conditions related to incorrect proliferation or incorrect migration of smooth muscle cells, tumours and cancers, cutaneous stress, chronic inflammatory diseases, in particular rheumatoid arthritis, and pulmonary inflammatory diseases).



(21) 549331 (22) 11 Mar 2005

(54) Imidazole compounds for the treatment of neurodegenerative disorders

(86) PCT/IB2005/000659 (87) WO2005/092864

(51) IPC2010.01:C07D233/88; C07D417/14; A61K31/4164; A61P25/28

(71) PFIZER PRODUCTS INC.


(72) Brodney, Michael Aaron; Coffman, Karen Jean;

(31) 04 555623 (32) 23 Mar 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is an imidazole compound of the Formula I wherein the substituents are disclosed within the specification or a pharmaceutically acceptable salt thereof.

Also disclosed is the use of a compound of Formula I in the manufacture of a medicament for inhibiting Abeta-peptide production in a mammal.



(21) 549437 (22) 25 Jan 2005

(54) Auxiliary supporting unit, boarding bridge with the same and method for improving stability of the boarding bridge by using the same

(86) PCT/CN2005/000107 (87) WO2005/082713

(51) IPC2010.01:B64D9/00; B64F1/305


(71) China International Marine Containers (Group) Co., Ltd

(72) Shen, Hongsheng; Zheng, Zuhua; Zhang, Zhaohong; Tan, Li;

(31) 04 10004652 (32) 26 Feb 2004 (33) CN

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) An aircraft boarding bridge includes a passenger tunnel, tunnel elevator, and a wheel mechanism 10 supporting the tunnel and drivable to extend or retract the tunnel. The wheel mechanism includes a beam 2 for supporting the elevator and ground contacting wheels 1 attached to the beam through a bearing assembly 21. An auxiliary supporting unit provides auxiliary support to the tunnel both when the bridge is moving and when located on position. The auxiliary supporting unit includes two leg supports 20 attached under the respective ends of the beam outside of the wheels, the leg supports being able to be driven to extend and retract, and two foot portions 25 each attached to the distal ends of the respective leg portions. When the legs are extended the foot portions come in contact with the ground and when the legs are retracted the feet are lifted off the ground. The feet may be small wheels. Thus two large dollies like to dolly 1 and with integrated driving and steering requirements may be replaced by a single main wheel dolly 1 and the auxiliary dollies 20.



(21) 549444 (22) 3 Feb 2005

(54) Infection-preventing gastrostomy catheter kit for gastrostomy

(86) PCT/EP2005/001074 (87) WO2005/074819

(51) IPC2010.01:A61M25/01,16; A61J15/00

(71) Covidien AG

(72) Abe, Kazuhiro; Suzuki, Nobuaki; Funamura, Shigeaki;

(31) 04 026348 (32) 3 Feb 2004 (33) JP

(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market Street, Sydney, New South Wales 2000, Australia

(57) Disclosed is an infection-preventing gastrostomy catheter kit to be used in the gastrostomy, which can pass an intragastric retainer of a catheter easily and reliably through an infection-preventing sheath by an easy maneuver, and which can reduce the diameter of the infection-preventing sheath. The catheter kit comprises: a gastrostomy catheter (20) including a flexible, hollow PEG tube (21) reinforced with filaments, an deformable intragastric retainer (23) positioned at the trailing end of the PEG tube (21), and a tapered member (22) positioned at the leading end of the PEG tube (21) for retaining the leading end portion (40a) of a guide wire (40) inserted from a leading end hole (22a) thereof; ; and an infection-preventing sheath (1) including a flexible, hollow tubular body (2), and a socket member having a socket (4) positioned at the trailing end of the tubular body (2) for retaining the intragastric retainer (23), and pins (5), thereby removably sheathing the gastrostomy catheter (20). The gastrostomy catheter (20) may be provided with a housing sheath for deforming and housing the intragastric retainer (23).

(21) 549570 (22) 23 Mar 2005

(54) Tricyclic benzopyran compound as anti-arrhythmic agents

(86) PCT/JP2005/006004 (87) WO2005/090357

(51) IPC2010.01:C07D498/04; C07D491/04; C07D513/04; C07D515/04; A61K31/436; A61P9/06

(71) Nissan Chemical Industries, Ltd.


(72) Ohrai, Kazuhiko; Uesugi, Osamu; Okada, Takumi; Shigeta, Yukihiro; Matsuda, Tomoyuki;

(31) 04 084605 (32) 23 Mar 2004 (33) JP

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed are tricyclic benzopyran compounds of formula (I) or pharmaceutical acceptable salts thereof, wherein the substituents are disclosed within the specification. Also disclosed is the use of the compounds of formula (I) for the production of a medicament for treating arrhythmia.

Divisional filed as 585606



(21) 549587 (22) 2 Feb 2005

(54) Device for nitriding by ionic implantation of an aluminium alloy part, and corresponding method

(86) PCT/FR2005/000224 (87) WO2005/085491

(51) IPC2010.01:C23C14/48; C23C8/36

(71) SOCIETE QUERTECH INGENIERIE (QI)

(72) Guernalec, Frederic; Busardo, Denis;


(31) 04 01047 (32) 4 Feb 2004 (33) FR

(31) 04 01749 (32) 21 Feb 2004 (33) FR

(31) 05 00963 (32) 31 Jan 2005 (33) FR

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A process for treating an aluminium alloy part by ion implantation comprises providing an apparatus comprising a source delivering ions accelerated by an extraction voltage, and first adjusting means for adjusting an initial beam of ions emitted by the source into an implantation beam. The source is an electron cyclotron source producing multi-energy ions. The multi-energy ions are implanted in the part at a temperature below 120°C. The implantation of the multi-energy ions from the implantation beam is effected simultaneously at a depth controlled by the extraction voltage of the source.



(21) 549721 (22) 7 Mar 2005

(54) Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects

(86) PCT/US2005/007435 (87) WO2005/087234

(51) IPC2010.01:A61K31/21,405,445

(71) The Trustees of the University of Pennsylvania

(72) Rader, Daniel J;

(31) 04 550915 (32) 5 Mar 2004 (33) US

(74) Pizeys Patent and Trade Mark Attorneys, Level 14, ANZ Centre, 324 Queen Street, Brisbane, Queensland 4000, Australia

(57) Disclosed is the use of an effective amount of an MTP inhibitor in the preparation of a medicament for administration to a subject suffering from a disorder associated with hyperlipidemia and/or hypercholesterolemia, wherein the medicament is formulated for administration according to a dosage regime that comprises at least three step-wise increasing dosage levels of the MTP inhibitor wherein a first dose level is from about 2 to about 13mg/day, a second dose level is from

about 5 to about 30 mg/day, and a third dose level is from about 10 to about 50mg/day wherein each dose level is administered to the subject for about 1 to 4 weeks; and where the MTP inhibitor is represented by formula (I) (known as BMS-201038) or a pharmaceutically acceptable salt thereof or the piperidine N-oxide thereof.

(21) 549748 (22) 7 Mar 2005

(54) A toothbrush head having a flexible bristle carrier capable of resiliently bending under the forces of toothbrushing

(86) PCT/EP2005/002471 (87) WO2005/084486

(51) IPC2010.01:A46B3/20; A46B7/06; A46B9/04,12

(71) GLAXOSMITHKLINE CONSUMER HEALTHCARE GMBH & CO KG


(72) Clos, Thomas; Kraemer, Hans;

(31) 04 0405314 (32) 9 Mar 2004 (33) GB

(31) 04 0410840 (32) 14 May 2004 (33) GB

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) A toothbrush head, connected or connectable to a toothbrush grip handle to define a head-handle length direction, with a width direction perpendicular to the longitudinal direction, is disclosed. The toothbrush head comprises a flexible bristle carrier, on which bristles are mounted, a base part closest to the toothbrush handle when connected, a longitudinally opposite tip part, and a support which supports the carrier. The support supports the carrier at the base part and at the tip part, leaving the carrier unsupported in a region longitudinally between these parts. The carrier is flexible such that it can deform under the forces of toothbrushing so that both its longitudinal and widthways sections become distorted. The support is capable of resilient bending deformation so that under the forces encountered in toothbrushing the tip part of the carrier can move resiliently to follow an arc in a plane perpendicular to the width direction.



(21) 549904 (22) 4 Apr 2005

(54) Thiadiazolidinones as GSK-3 inhibitors

(86) PCT/EP2005/003613 (87) WO2005/097117

(51) IPC2010.01:C07D285/08; C07D417/04; A61K31/433; A61P25/28; A61P3/10


(71) Noscira S.A.

(72) Martinez Gil, Ana; Dorronsoro Diaz, Isabel; Alonso Cascon, Mercedes; Panizo Del Pliego, Gema; Fuertes Huerta, Ana; Perez Puerto, Maria Jose; Medina Padilla, Miguel;

(31) 04 04075997 (32) 5 Apr 2004(33) EP

(74) FISHER ADAMS KELLY, Level 29, 12 Creek Street, Brisbane, Queensland 4000, Australia

(57) Disclosed are thiadiazolidinone compounds of formula (I) wherein the substituents are as defined in the specification, which is of inhibitors of glycogen synthase kinase 3-beta (GSK-3), processes of preparation and its use for treating GSK-3 associated diseases such as Alzheimer's disease or non-insulin dependent diabetes mellitus.



(21) 549925 (22) 6 Apr 2005

(54) Inhibitors of IAP

(86) PCT/EP2005/003619 (87) WO2005/097791

(51) IPC2010.01:A61K31/40,4025,437,55; C07D207/06,08,09; C07D401/04,12; C07D403/04,12; C07D405/12; C07D409/12; C07D413/04,14; C07D417/04; C07D471/04; C07D487/04

(71) Novartis AG

(72) Palmero, Mark G; Sharma, Sushil kumar; Straub, Christopher; Wang, Run-Ming; Zawal, Leigh; Zhang, Yanlin; Chen, Zhuoliang; Wang, Yaping; Yang, Fan; Wrona, Wojciech; Liu, Gang; Charest, Mark G; He, Feng;

(31) 04 560186 (32) 7 Apr 2004(33) US

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (IVa). Compounds of formula IVa are useful for the treatment of proliferative diseases, including cancer.

(21) 549977 (22) 22 Feb 2005

(54) System and methods for multiple wells from a common surface location

(86) PCT/US2005/005289 (87) WO2005/093211

(51) IPC2010.01:E21B43/00,30

(71) CDX Gas, LLC


(72) Zupanick, Joseph A;

(31) 04 788694 (32) 27 Feb 2004 (33) US

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) A method and system for accessing a subterranean zone is disclosed.

The method comprises: (a) forming an entry well from the surface where the entry well has a substantially vertical portion, (b) forming one or more drainage wells from the entry well to a subterranean zone where each drainage well comprises at least one slanted portion, (c) forming one or more articulated wells from the entry well to the subterranean zone where at least one articulated well intersects at least one of the drainage wells at a junction proximate the subterranean zone, and (d) forming a drainage pattern coupled to the junction which is operable to conduct fluid from the subterranean zone to the junction.



(21) 550010 (22) 24 Mar 2005

(54) 8-hydroxy-5-[(1R)-1-hydroxy-2-[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride in crystalline form and the process for its preparation

(86) PCT/EP2005/003144 (87) WO2005/089760

(51) IPC2010.01:A61K31/47; C07D207/48; C07D215/26,60

(71) CHIESI FARMACEUTICI S.p.A.

(72) Pivetti, Fausto; Pighi, Roberto;

(31) 04 04007045 (32) 24 Mar 2004 (33) EP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2-[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1 H)-quinolinone mono-hydrochloride (I) comprising crystallising or re-crystallising compound (I) from an ethanol-water mixture in a ratio from 97:3 to

95:5 added with diisopropyl ether, wherein the ethanol-water mixture is concentrated under reduced pressure at a temperature comprised between 30 and 55 Deg. C to a volume comprised between 1/2 and 1/3 of the initial volume and the addition of the diisopropyl ether is performed in at least 5 minutes.

(21) 550149 (22) 28 Apr 2005

(54) Natural gas liquefaction using a more efficient process

(86) PCT/US2005/014814 (87) WO2005/108890

(51) IPC2010.01:F25J1/00; F25J3/00; F25J1/02

(71) Ortloff Engineers, Ltd.

(72) Wilkinson, John D; Lynch, Joe T; Hudson, Hank M; Cuellar, Kyle T;

(31) 04 840072 (32) 4 May 2004 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) A process for liquefying natural gas in conjunction with producing a liquid stream containing predominantly hydrocarbons heavier than methane is disclosed. In the process, the natural gas stream to be liquefied is partially cooled and divided into first and second streams. The first stream is further cooled to condense substantially all of it, expanded to an intermediate pressure, and then supplied to a distillation column at a first mid-column feed position. The second stream is also expanded to intermediate pressure and is then supplied to the column at a second lower mid-column feed position. A distillation stream is withdrawn from the column below the feed point of the second stream and is cooled to condense at least a part of it, forming a reflux stream and a residual vapour stream. At least a portion of the reflux stream is directed to the distillation column as a top feed. The residual vapour stream is combined with the more volatile vapour distillation stream from the top of the distillation column to form a volatile residue gas fraction containing a major portion of the methane and lighter components. The volatile residue gas fraction is cooled under pressure to condense at least a portion of it and form the condensed liquid stream (LNG).

(21) 550168 (22) 26 Feb 2005

(54) An apparatus for transferring torque magnetically

(86) PCT/US2005/006179 (87) WO2005/086330

(51) IPC2010.01:H02K49/10; H02K51/00; H02K49/02

(71) Flux Drive, Inc.


(72) CORBIN, Philip; DAHLIN, Robert L; MOLNAR, John A; RUSCONI, John B; STRONG, Walter F;

(31) 04 790571 (32) 1 Mar 2004 (33) US

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) An apparatus for transferring torque magnetically is disclosed. The apparatus comprises a primary torque driving rotary member and a secondary driven rotary member. The primary rotary member axially overlaps the secondary rotary member where the secondary rotary member is surrounded by the primary member. The primary rotary member has permanent magnets mounted onto it and the secondary rotary member has electroconductive elements and magnetically permeable materials, neither of which are ferromagnetic, and does not have permanent magnets. A means for varying the primary rotary member's axial position relative to the secondary rotating member is provided. The primary rotating member is connected to and driven by a torque producing device and the secondary rotating member is connected to a torque utilizing device whereby rotation of the primary rotary member causes rotation of the secondary rotating member by magnetic interaction thereby generating torque and rotation in the secondary rotary member in respect to the percentage of the total area the secondary rotary member is axially overlapped by the primary rotary member.

Divisional filed as 586326



(21) 550177 (22) 7 Mar 2005

(54) Process for cross coupling in doles

(86) PCT/US2005/006919 (87) WO2005/092855

(51) IPC2010.01:C07D209/30


(71) BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.

(72) Khodabocus, Ahmad; Li, Guisheng; Lu, Zhi-Hui; Roschangar, Frank; Senanayake, Chris H; Shen, Ming;

(31) 04 551107 (32) 8 Mar 2004 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) A process for making a substituted indole derivative of formula (I) is disclosed, wherein said process comprises: reacting a substituted indole compound of formula (I') with a heteroaryl or aryl zinc halide or di-heteroaryl or di-aryl zinc compound as defined in the specification, wherein the variables are as defined in the specification, and wherein the reaction is carried out in the presence of a metal catalyst selected from Pd and Ni, a ligand selected from mono-dentate triphenylphosphine (Ph₃P), tri-p-tolylphosphine (p-Tol₃P), tricyclohexylphosphine (PCy₃), tri-t-butylphosphine (t-Bu₃P), (Cy₂P(Ph-Ph)) and bi-dentate 1,1'-bis(diphenylphosphino)ferrocene (dppf), 1,4-bis(diphenylphosphino)ferrocene (dppb), in a solvent selected from tetrahydrofuran (THF), dimethoxyethane (DME), dimethylformamide (DMF), 1-methyl-2-pyrrolidinone (NMP) or a combination thereof, at a temperature of between ambient and 100 Deg. C, to provide the desired compound of formula (I).



(21) 550192 (22) 5 Jul 2005

(54) Nanocomposite composition having super barrier property and article using the same

(86) PCT/KR2005/002147 (87) WO2006/098534

(51) IPC2010.01:C08J5/18; C08K9/00; C08L23/06,26

(71) LG CHEM. LTD.

(72) Kim, Myung-Ho; Lee, Shi-Ho; Yang, Young-Chul; Yang, Ku Min;

(31) 05 80747 (32) 15 Mar 2005 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a nanocomposite composition comprising:

1 to 97 wt % of a polyolefin resin;

I to 95 wt % of a nanocomposite comprising a resin having barrier properties and an intercalated clay, at a weight ratio of 58.0:42.0 to 99.9:0.1, wherein the resin having barrier properties is an amorphous polyamide having a glass transition temperature of about 70 to 170°C, optionally further comprising an ethylene-vinyl alcohol copolymer, a non-amorphous polyamide, an ionomer, a polyvinyl alcohol, or a combination of one or more of the foregoing resins; and 1 to 95 wt % of a compatibilizer, said compatibilizer being selected from a list provided in the specification.

(21) 550193 (22) 15 Apr 2005

(54) Overmolded vial for use with a level where the level marks are protected between two plastic layers

(86) PCT/US2005/013038 (87) WO2005/103613

(51) IPC2010.01:G01C9/26,24,34; B29D23/00

(71) EMPIRE LEVEL MFG. CORP.

(72) Foran, Thomas P;

(31) 04 826853 (32) 16 Apr 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A vial (10) and method for manufacturing a vial (10) for a level is disclosed. When manufacturing vials they require an internal shape like a classic barrel. This ensures that the bubble is in the middle of the vial when level. If the vial is manufactured so that the walls are thin enough to allow the flex necessary to remove a core pin used to mould the cavity the vial will not have sufficient strength. If formed then over moulded this problem is overcome. The vial (10) is constructed from a first cylinder (20) which is over-moulded by injection moulding using a plastics material to form a sleeve (31). This assembly is to protect indicia (40) or rings (41) on the surface of the first cylinder (20) and improve the strength of the vial (10). The vial (10) in operation contains a liquid (51) and bubble (50) held in by a cap (13) and is inserted into a level.



(21) 550224 (22) 4 Apr 2005

(54) A film that uses an oxide of nitrogen to create nitroxymyoglobin and maintain the red colour of fresh meat

(86) PCT/US2005/011387 (87) WO2005/097486

(51) IPC2010.01:B32B9/04; B65B31/00; C01B21/20; A23B4/02


(71) CURWOOD, INC.

(72) Siegel, Dan G; Nelson, Kevin Philip;

(31) 04 559350 (32) 2 Apr 2004(33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) A food packaging film (22) is disclosed. The film is used in creating and stabilizing a desirable colour on the surface of a food (100), such as raw meat without deleteriously affecting the subsurface colour. The film (22) comprises a food contact layer and a nitrogen oxide-containing compound. The film forms a package (10') to hold the food (100) and also acts as an oxygen barrier. The nitrogen oxide-containing compound interacts with myoglobin in the food (100) to produce the desirable colour. The amount of nitrogen oxide-containing compound is insufficient to cure the entire food (100) and is present at a transferable amount of at least 1.24 milligrams per square meter (0.0008 milligrams per square inch) at the surface of the film.



(21) 550263 (22) 30 Mar 2005

(54) Improvements relating to socks

(86) PCT/GB2005/001203 (87) WO2005/094738

(51) IPC2010.01:A44B11/02; A61F13/06,08; A61F15/00


(71) CONVATEC TECHNOLOGIES, INC.

(72) Adams, Simon Mark; Bonnefin, Wayne Lee; Hanmer, Paul; Linnane, Patrick Gerard; Rowley, Duncan John; Tabron, Ian Stewart; Wild, David Geoffrey;

(31) 04 7371 (32) 31 Mar 2004 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A compression therapy kit comprises a sock (101a, 101b) suitable for wearing on a limb of a patient. The sock comprises material having the ability to wick moisture away from the skin surface and the sock comprises padding (107, 108) located in those areas of the sock which in use will cover the ankle and shin of the patient and one or more compression applying means which in use apply compression over the sock to the ankle and shin of the patient.



(21) 550326 (22) 8 Apr 2005

(54) Sustained release formulation for oral administration of HMG-CoA reductase inhibitor such as simvastatin and method for the preparation thereof

(86) PCT/KR2005/001021 (87) WO2005/097194

(51) IPC2010.01:A61K47/00; A61P9/10; A61K9/22; A61P9/00

(71) HANMI PHARM. CO., LTD.

(72) Woo, Jong-Soo; Yi, Hong-Gi; Chi, Moon-Hyuk; Ryu, Jae-Kuk; Jung, Si-Young; Kim, Yong-Il;

(31) 04 040024734 (32) 10 Apr 2004 (33) KR

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a sustained release formulation for oral administration of an HMG-CoA reductase inhibitor comprising:
a solid dispersant containing the HMG-CoA reductase inhibitor, a solubilising agent, and a stabilizing agent;
a mixture of sodium alginate and xanthan gum as a sustained release composite carrier; and
a mixture of propylene glycol ester alginate and hydroxypropyl methylcellulose as a gel hydration accelerator.

(21) 550340 (22) 16 Mar 2005

(54) Prevention of retinopathy by inhibition of the visual cycle using a retinoid

(86) PCT/DK2005/00176 (87) WO2005/087210

(51) IPC2010.01:A61K31/05,07,136,192,203,4436


(71) LARS MICHAEL LARSEN

(72) Larsen, Lars Michael;

(31) 04 00431 (32) 17 Mar 2004 (33) DK

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, Victoria 3000, Australia

(57) Disclosed is the use of a compound of formula (V), wherein R11 is as defined in the specification, and wherein the double bonds may be cis or trans as defined in the specification, for the treatment of preproliferative diabetic retinopathy and of macular edema.



(21) 550412 (22) 6 May 2005

(54) Method and composition for treating rhinitis

(86) PCT/GB2005/001758 (87) WO2005/107711

(51) IPC2010.01:A61K31/495; A61K9/00, 127; A61P37/08

(71) BIOLIPOX AB

(72) Pereswetoff-Morath, Lena; Carlsson, Anders;

(31) 04 842433 (32) 11 May 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) The disclosure relates to a homogeneous pharmaceutical composition for the treatment of rhinitis by nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier. Also disclosed is a process for the preparation of said composition and the use of said composition for the manufacture of a medicament for the treatment of rhinitis.

(21) 550474 (22) 5 Apr 2005

(54) Cable anchor bracket with protrusions to engage in guardrail apertures

(86) PCT/US2005/011266 (87) WO2005/100694

(51) IPC2010.01:E01F15/14


(71) The Texas A & M University System; Trinity Industries, Inc.

(72) Butth, C Eugene; Ross, Hayes E; Brown, Stephen L; Alberson, Dean C; Bligh, Roger P; Bullard, D Lance;

(31) 04 819526 (32) 7 Apr 2004 (33) US

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia

(57) According to one embodiment, a cable anchor system for an end terminal (104) includes a cable anchor bracket (108) configured to couple to a guardrail (102), in which the cable anchor bracket includes a flat plate having an aperture for receiving a cable end formed therein and a plurality of protrusions (112) extending from a plane containing the aperture. The protrusions are configured to releasably engage the guardrail by virtue of complementary apertures in the guardrail.



(21) 550477 (22) 12 Mar 2005

(54) Securing elements to pipes and tubes using a two part securing device that locks around the pipe or tube using a sliding movement

(86) PCT/AU2005/000343 (87) WO2005/088181

(51) IPC2010.01:F16L3/24, 00, 12


(71) Raymond Rabanin

(72) Rabanin, Raymond;

(31) 2004 901265 (32) 12 Mar 2004 (33) AU

(74) MORCOM PERNAT, Suite 10, 475 Blackburn Road, Mount Waverley, Victoria 3149, Australia

(57) A securing device for securing items to a pipe comprises a first part 4 and a second part 3 which can be positioned in engagement with each other when placed around a pipe. The first part 4 is placed behind a pipe and then the second part 3 is placed on the other side of the pipe below the first part 4. The then second part 3 is slid upwards until its flanges 10 enter into and engage with the recesses 15 on the first part 4. The surfaces of both the flanges 10 and the recesses 15 are inclined relative to the plane of the pipe such that the two parts of the securing device are drawn together as the second part 3 enters the first part 4. This drawing together of both parts of the device causes the device to grip the pipe when the two parts 3 4 of the device are approximately opposite to each other.



(21) 550482 (22) 15 Apr 2005

(54) Use of peptidic compounds for the prophylaxis and treatment of chronic headache

(86) PCT/EP2005/004047 (87) WO2005/099740

(51) IPC2010.01:A61K31/16, 165; A61K38/03, 05; A61P25/06


(71) SCHWARZ PHARMA AG

(72) Scheller, Dieter; Stohr, Thomas;

(31) 04 562681 (32) 16 Apr 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is the use of a compound having the Formula (IIb) wherein Ar is phenyl which is unsubstituted or substituted with at least one halo group; R3 is CH2-Q, wherein Q is alkoxy containing 1-6 carbon atoms, and R1 is alkyl containing 1-6 carbon atoms or of a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the prevention of migraine.



(21) 550489 (22) 14 Mar 2005

(54) Mattress with surface channels in inclined portion to dissipate body heat away, typically for babies

(86) PCT/EP2005/002706 (87) WO2005/092154

(51) IPC2010.01:A47C27/00, 14; A47D7/00; A47D15/00

(71) Sprog Ltd; Philip Owen

(72) Owen, Philip;

(31) 04 06225 (32) 19 Mar 2004 (33) GB

(74) J.D. Hardie & Co, 14th Floor, 48 Emily Place, Auckland, New Zealand

(57) A mattress (2), comprising: a resilient body having at least one upper surface portion for supporting a person (such as a small child or baby); and a plurality of surface channels (30) disposed in the or each upper surface portion and extending parallel thereto. The upper surface por-

tions (for example three, including separate surface portions for supporting the head and the body) are inclined relative to the horizontal (or preferably, suitably anatomically sloped). The surface channels (30) have a component of direction in the direction of rising slope. In consequence, warm air that has been heated by contact with the person's body, in order to rise, passes along the surface channel (30) and out to the surrounding atmosphere. Thus, heat is dissipated away from the person's body and helps to prevent overheating.

(21) 550522 (22) 24 Mar 2005

(54) Synthesis of boronic ester and acid compounds

(86) PCT/US2005/009774 (87) WO2005/097809

(51) IPC2010.01:C07F5/02,04

(71) MILLENNIUM PHARMACEUTICALS, INC.

(72) PICKERSGILL, I Fraser; BISHOP, John; KOELLNER, Christoph; GOMEZ, Jean-Marc; GEISER, Achim; HETT, Robert; AMMOSCATO, Vince; MUNK, Stephen; LO, Young; CHUI, Fang-Ting; KULKARNI, Vithalanand R;


(31) 04 557535 (32) 30 Mar 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is a large-scale process for preparing a boronic ester compound of formula (I), wherein the substituents are as defined in the specification, which comprises taking a boron "ate" complex of formula (II), wherein Y is a nucleofugic group, and contacting the complex with a Lewis acid in a reaction mixture that has a low miscibility with water.

Also disclosed are other methods of producing boronic compounds, which involve reacting a boron "ate" complex with a Lewis acid in a solvent that has a low miscibility with water. Also claimed are compositions containing at least ten moles of the compound of formula (I) in an ether solvent that has a low miscibility with water.

Divisional filed as 586824



(21) 550587 (22) 13 Apr 2005

(54) Closure device with multiple coloured closure elements

(86) PCT/US2005/012403 (87) WO2005/108225

(51) IPC2010.01:B65D33/16; A44B5/00; A44B19/16


(71) THE GLAD PRODUCTS COMPANY

(72) Borchardt, Michael G; Cisek, Ronald J;

(31) 04 832154 (32) 26 Apr 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A bag closure device 221 comprises two fastening strips 249 250, with the first fastening strip 249 having first and second male closure elements 245 246 and the second fastening strip 250 having first and second female closure elements 247 248. On the first fastening strip 249 the first male closure element 245 has a first colour and the second male closure element 246 has a second colour. On the second fastening strip 250 the first female closure element 247 has a third colour and the second female closure element 248 has a fourth colour. On interlocking the two fastening strips 249 250, the first male closure element 245 with the first colour will interlock with the first female closure element 247 with the third colour producing a fifth colour. The second male fastening element 246 with the second colour will interlock with the second female fastening element 248 with the fourth colour producing a sixth colour.



(21) 550588 (22) 13 Apr 2005

(54) Closure device providing visual confirmation of occlusion

(86) PCT/US2005/012400 (87) WO2005/108224

(51) IPC2010.01:B65D33/16,24


(71) THE GLAD PRODUCTS COMPANY

(72) Borchardt, Michael G; Cisek, Ronald J;

(31) 04 831801 (32) 26 Apr 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A closure 130, 131 for the likes of a "zip lock" bag 27 includes a surface alteration such as a slit 163 on at least one of the closure strips 134 that opens or closes upon occlusion of the closure to provide a visual confirmation of the occlusion. The surface alteration extends through a first material of the closure and into a second material 165 of the closure; the first material substantially surrounding the second material. When the surface alteration is closed the second material 165 is hidden from view so that when the surface alteration is opened when the closure is occluded, the second material which may be of a distinctive colour is visible.



(21) 550664 (22) 19 Apr 2005

(54) Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

(86) PCT/EP2005/004166 (87) WO2005/102300

(51) IPC2010.01:A61K31/165,198,381,40; A61K45/06

(71) NEWRON PHARMACEUTICALS S.P.A.

(72) Besana, Claudia; Barbanti, Elena; Izzo, Emanuela; Thaler, Florian; Fariello, Ruggero; Salvati, Patricia; Benatti, Luca;

(31) 04009532 (32) 22 Apr 2004 (33) EP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is the use of alpha-aminoamide derivatives for the preparation of a medicament for treating Restless Leg Syndrome (RLS) and addictive disorders. Particular addictive disorders are drug abuse, severe alcoholism and reward deficiency syndrome (RDS). The compounds, which are listed in the specification, are a chemical class of monoamine oxidase B (MAOB) inhibitors, sodium channel blockers, dopamine re-uptake inhibitors and glutamate levels modulators.

(21) 550670 (22) 28 Apr 2005

(54) Earth-boring bits

(86) PCT/US2005/014742 (87) WO2005/106183

(51) IPC2010.01:E21B10/46

(71) TDY INDUSTRIES, INC.; BAKER HUGHES INCORPORATED

(72) Mirchandani, Prakash K; Eason, Jimmy W; Oakes, James J; Westhoff, James C; Collins, Gabriel B; Stevens, John H; Mosco, Alfred J; Caldwell, Steven G;

(31) 04 566063 (32) 28 Apr 2004 (33) US

(31) 04 848437 (32) 18 May 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A bit body, roller cone, insert roller cone, or cone for an earth-boring bit is disclosed. The bit body, roller cone, insert roller cone, or cone for an earth-boring bit comprises a body material which comprises hard particles having at least one of a carbide, a nitride, a boride, a silicide, an oxide, and solid solutions thereof, and a binder. The binder comprises at least one metal selected from cobalt, nickel, iron and alloys thereof, and at least one melting point reducing constituent selected from at least one of a transition metal carbide up to 60 weight percent, a transition metal boride up to 60 weight percent, and a transition metal silicide up to 60 weight percent, wherein the weight percentages are based on the total weight of the binder, and where the binder has a melting point in the range of 1050°C to 1350°C.

(21) 550737 (22) 6 May 2005

(54) New hydroxapatite calcium phosphates, their method of preparation and their applications

(86) PCT/US2005/015684 (87) WO2005/115418

(51) IPC2010.01:A61K33/42,36; A01N59/26,22

(71) INNOPHOS, INC.

(72) Godber, John; Leite, Lorraine;

(31) 04 04900 (32) 6 May 2004 (33) FR

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a composition comprising calcium phosphate in granular form having an X-ray diffraction pattern characteristic of hydroxyapatite in which up to 10% of the phosphate anions of the crystal lattice are substituted with carbonate anions, and wherein the size of the calcium phosphate granules expressed by the median diameter (d50) is between 100 and 250 micrometer. Also disclosed is a method of preparing a calcium phosphate in granular form with an X-ray diffraction pattern characteristic of hydroxyapatite comprising the steps of: providing an aqueous suspension of brushite dicalcium phosphate in a reaction vessel, wherein the brushite dicalcium phosphate has a particle size distribution such that the median diameter (d50) is between 100 and 250 micrometer; adding a solution of an alkaline earth carbonate base to the brushite dicalcium phosphate suspension; and mixing the suspension for a sufficient amount of time to allow the transformation of the brushite dicalcium phosphate into hydroxyapatite calcium phosphate.

(21) 550797 (22) 18 Apr 2005

(54) Pharmaceutical combinations containing 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one for treating respiratory diseases

(86) PCT/EP2005/004073 (87) WO2005/102349

(51) IPC2010.01:A61K31/538; A61P11/06; C07D265/36

(71) BOEHRINGER INGELHEIM INTERNATIONAL GMBH

(72) Bouyssou, Thierry; Konetzki, Ingo; Pestel, Sabine; Schnapp, Andreas; Hoenke, Christoph; Lustenberger, Philipp; Rudolf, Klaus; Pieper, Michael P; Pairet, Michel;

(31) 04 019540 (32) 22 Apr 2004 (33) DE


(31) 04 052987 (32) 3 Nov 2004 (33) DE

(31) 05 05002496 (32) 7 Feb 2005 (33) EP

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a medicament combination which comprises 6-hydroxy-8-{1-hydroxy-2-[2-(4-methoxy-phenyl)-1,1-dimethylethylamino]-ethyl}-4H-benzo[1,4]oxazin-3-one (as represented by the formula 1.5) and one or two compounds as another active substance 2 selected from anticholinergics (2a) and steroids (2c); wherein any anticholinergic (2a) is selected from the group comprising tiotropium salts (2a.1), oxitropium salts (2a.2), flutropium salts (2a.3), ipratropium salts (2a.4), glycopyrronium salts (2a.5), trospium salts (2a.6) and any steroid 2c is

selected from the group comprising prednisolone (2c.1), prednisone (2c.2), butixocortpropionate (2c.3), flunisolide (2c.5), beclomethasone (2c.6), triamcinolone (2c.7), budesonide (2c.8), fluticasone (2c.9), mometasone (2c.10), ciclesonide (2c.11), rofleponide (2c.12), dexamethasone (2c.14), (S)-fluoromethyl 6a,9a-difluoro-17a-[(2-furanylcarbonyloxy)-11b-hydroxy-16a-methyl-3-oxo-androsta-1,4-diene-17b-carbothionate (2c.15), (S)-(2-oxo-tetrahydro-furan-3S-yl) 6a,9a-difluoro-11b-hydroxy-16a-methyl-3-oxo-17a-propionyloxy-androsta-1,4-diene-17b-carbothionate (2c.16) and etiprednol-dichloroacetate (2c.17), optionally in the form of a racemate, enantiomer or diastereomer thereof and optionally in the form of a salt or functional derivative thereof, solvate and/or hydrate thereof. Also disclosed is the use of a medicament combination as defined above for preparing a pharmaceutical composition for the treatment of inflammatory and obstructive respiratory complaints (such as obstructive pulmonary diseases of various origins, pulmonary emphysema of various origins, restrictive pulmonary diseases, interstitial pulmonary diseases, cystic fibrosis, bronchitis of various origins, bronchiectasis, ARDS (adult respiratory distress syndrome) and all forms of pulmonary oedema, bronchial asthma, paediatric asthma, severe asthma, acute asthma attacks, chronic bronchitis and COPD (chronic obstructive pulmonary disease)).



(21) 550876 (22) 4 May 2005

(54) Functionalised siloxanes for scar tissue treatment

(86) PCT/AU2005/000630 (87) WO2005/105115

(51) IPC2010.01:A61K31/80; A61L27/60; A61P17/02


(71) Queensland University of Technology

(72) Sanchez, Washington; George, Graeme Allan;

(31) 04 568109 (32) 4 May 2004 (33) US

(74) FISHER ADAMS KELLY, Level 29, 12 Creek Street, Brisbane, Queensland 4000, Australia

(57) Disclosed is a composition comprising a compound of formula (I), wherein m is 1-6, n is 6-100, R and R' are methyl, each Q is VO(CH₂CH₂O)_yU or VOH, and U, V, and y are as defined in the specification, wherein the compounds makes up at least 1% of the composition. Also described is the use of the above composition for treating a wound, burn, or skin condition.



(21) 550878 (22) 29 Mar 2005

(54) Coating composition, coated article and a method to manufacture the same

(86) PCT/IB2005/001308 (87) WO2005/094161

(51) IPC2010.01:B29B15/12; C08K3/34; C09D5/02; C09D7/12; E04C2/04

(71) COVERIGHT SURFACES HOLDING GMBH

(72) Huang, Yo-Bu;

(31) 04 557779 (32) 30 Mar 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
 (57) Disclosed is a coating composition comprising two or more pigments, an organic binder and at least one thickener, wherein the coating composition has an absolute viscosity of 6000 to 30000 millipascals and wherein the coating composition comprises 55 – 70 percent by weight, solid and wherein the coating composition comprises a phyllosilicate or a phyllosilicate-comprising clay as a first pigment and an inosilicate or an inosilicate-comprising clay as a second pigment. Also disclosed is a coated article comprising said coating composition.

(21) 550946 (22) 19 May 2005
 (54) A teatcup liner and a teatcup
 (86) PCT/SE2005/000747 (87) WO2005/120216
 (51) IPC2010.01:A01J5/08
 (71) DeLAVAL HOLDING AB


(72) Kassibrahim, Jan; Petterson, Torbjorn;

(31) 04 0401484 (32) 10 Jun 2004 (33) SE

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is a teatcup liner (1) which is mounted in a shell (2) of the teatcup and defines an inner space (3) for receiving a teat. The liner includes a primary component (11) which forms an upper head of the teatcup. The primary component includes a primary peripheral portion (15), a primary connecting ring (16) and a lip (17) defining an opening (4) for the introduction of the teat. The liner further includes a secondary component (12) which forms a barrel of the teatcup. The secondary component includes a secondary peripheral portion (18) and a secondary connecting ring (20). The primary component is connectable to the secondary component which realises the liner by a mutual engagement of the connecting rings. The connecting ring of at least one of the components abuts the peripheral portion of the other component to form a sealing abutment between the primary component and the secondary component.

Divisional filed as 586606



(21) 550978 (22) 23 Jun 2005
 (54) Compounds and methods for treating dyslipidemia
 (86) PCT/US2005/022389 (87) WO2006/002342
 (51) IPC2010.01:A61K31/55; A61P3/06; A61P9/10; C07D401/12,14; C07D403/12,14; C07D405/14; C07D409/14; C07D413/12; C07D417/12,14; C07D491/04

(71) ELI LILLY AND COMPANY

(72) Chen, Xinchao; Cioffi, Christopher Lawrence; Dinn, Sean Richard; Escribano, Ana Maria; Fernandez, Maria Carmen; Fields, Todd; Herr, Robert Jason; Mantlo, Nathan Bryan; Mateo-Herranz, Ana Isabel; Parthasarathy, Saravanan; Wang, Xiaodong; De La Nava, Eva Maria Martin;

(31) 04 582708 (32) 24 Jun 2004 (33) US


(31) 04 627241 (32) 12 Nov 2004 (33) US

(31) 05 664862 (32) 24 Mar 2005 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of Formula I wherein Y is a bond, C=O, or S(O)t; and wherein the rest of the substituents are disclosed within the specification; or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer or mixture of diastereomers thereof.

Also disclosed is the use of a compound of Formula I for the manufacture of a medicament for modulating CETP activity in a mammal.



(21) 550983 (22) 28 Apr 2005

(54) Fused quinoline derivative and use as an NK2 receptor antagonist

(86) PCT/JP2005/008558 (87) WO2005/105802

(51) IPC2010.01:C07D471/04; A61K31/4745


(71) Takeda Pharmaceutical Company Limited

(72) Kajino, Masahiro; Hird, Nicholas William; Tarui, Naoki; Banno, Hiroshi; Kawano, Yasuhiko; Inatomi, Nobuhiro;

(31) 04 134705 (32) 28 Apr 2004 (33) JP

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a compound of formula (I), or a salt thereof, wherein the substituents are as defined in the specification. Also disclosed is a method of producing the above compound, and its use as an NK2 receptor antagonist to treat functional gastrointestinal diseases such as irritable bowel syndrome or nonulcer dyspepsia.



(21) 551031 (22) 29 Apr 2005

(54) Methods of fabricating surgical blades from silicon wafers by etching

(86) PCT/US2005/015016 (87) WO2005/109488

(51) IPC2010.01:H01L21/302

(71) Becton Dickinson and Company


(72) Hughes, James; Daskal, Vadim; Keenan, Joseph; Kiss, Attila; Chavez, Susan;

(31) 04 566397 (32) 30 Apr 2004 (33) US

(31) 04 584850 (32) 2 Jul 2004 (33) US

(74) J.D. Hardie & Co, 14th Floor, 48 Emily Place, Auckland, New Zealand


(57) A method of forming a blade from a silicon wafer 202 by first cutting a V shaped trench on one surface of the silicon wafer 202 and then uniformly etching the V shaped trench until a blade is formed.



(21) 551074 (22) 3 May 2005
 (54) Method of assessment of airway variability in airway hyperresponsiveness
 (86) PCT/CA2005/000664 (87) WO2005/104944
 (51) IPC2010.01:A61B5/085; G06F17/18
 (71) Dalhousie University
 (72) Maksym, Geoffrey N; Lall, Carolyn A;
 (31) 04 567446 (32) 4 May 2004 (33) US
 (31) 04 630567 (32) 26 Nov 2004 (33) US
 (74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, Victoria, Australia
 (57) A method of assessment of airway variability in airway responsiveness or asthma is disclosed. The method includes:
 generating data representing airway resistance measured by a forced oscillation technique utilizing a plurality of oscillation frequencies during respiratory cycles of a patient;
 generating data representing the standard deviation of the airway resistance for the patient using the airway resistance data, and
 correlating the standard deviation of the airway resistance of the patient to a standard curve obtained from a population of asthmatics and non-asthmatics to quantify the degree of asthma of the patient.
 This method may also be used to determine the effectiveness of pharmacological agonists and antagonists.


(21) 551117 (22) 1 Sep 2005
 (54) Software distribution framework
 (86) PCT/US2005/031266 (87) WO2006/041591
 (51) IPC2010.01:G06Q99/00; H04L9/00; H04K1/00; G06F21/00
 (71) Insight Direct USA, Inc
 (72) Vaughan, Michael J; Jacobs, Erich K; Brusseau, Craig S; Dumont, Norman J; Penney, Bruce D; Covino, John M;
 (31) 04 961811 (32) 8 Oct 2004 (33) US
 (74) Pizeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza Offices, Woden Town Square, Woden, ACT 2606, Australia
 (57) A digital content distribution system comprises a credentialing authority component, an access control and a digital content distribution system interface.
 The credentialing authority component is configured to receive encryption keys associated with each of a plurality of participants in the digital content distribution system and assign each of the plurality of participants an identity certificate for use during subsequent interactions with components of the digital content distribution system. The access control component is configured to maintain information regarding access rights of the plurality of participants to digital content accessible via the digital content distribution system. The digital content distribution system interface corresponds to each of the plurality of participants. The digital content distribution system interface is capable of being customized for the corresponding participant and configured to coordinate interactions among the corresponding participant and the components of the digital content distribution system according to predetermined business processes associated with the corresponding participant. The plurality of participants includes one or more content publishers, a plurality of enterprise content consumers, and at least one seller or provider. The access control com-

ponent is configured to maintain information regarding access rights of each of the plurality of enterprise content consumers to software products made accessible via the digital content distribution system directly or indirectly from the plurality content publishers.



(21) 551125 (22) 11 May 2005
 (54) Crystalline forms of duloxetine free base
 (86) PCT/GB2005/001825 (87) WO2005/108386
 (51) IPC2010.01:C07D333/20; A61K31/381; A61P25/24
 (71) CIPLA LIMITED
 (72) Kankan, Rajendra Narayanrao; Rao, Dharmaraj Ramachandra; Srinivas, Pathi L; Ravikumar, Puppala;
 (31) 04 10470 (32) 11 May 2004 (33) GB
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) Disclosed is a duloxetine free base in crystalline form as well as specific forms A, B and C.
 Also disclosed is the process of preparing crystalline duloxetine free base comprising dissolving or suspending a salt of duloxetine in a suitable medium, neutralizing with a suitable base, extracting the thus formed duloxetine free base into a suitable solvent, replacing the solvent with a non-solvent, and thus isolating duloxetine free base in crystalline form.
 Also disclosed is the use of crystalline duloxetine free base in the manufacture of a medicament for treating depression.

(21) 551174 (22) 12 May 2005
 (54) Piperazin derivatives and their use in controlling pests
 (86) PCT/IB2005/001468 (87) WO2005/115146
 (51) IPC2010.01:A01N43/60; A01N47/20,30; C07D295/00; C07D401/00
 (71) Syngenta Participations AG
 (72) Cassayre, Jerome; Molleyres, Louis-Pierre; Maienfisch, Peter; Cederbaum, Fredrik; Corsi, Camilla; Pitterna, Thomas;
 (31) 04 0412072 (32) 28 May 2004 (33) GB
 (74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand
 (57) The disclosure relates to a method of combating and controlling insects, acarines, nematodes or molluscs, which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematocidally or molluscicidally effective amount of a compound of formula (I), wherein the variables shown in formula (I) are as defined in the specification.



(21) 551194 (22) 9 May 2005

(54) A Lead-free, armour piercing projectile with a hollow core

(86) PCT/CH2005/000257 (87) WO2005/108908

(51) IPC2010.01:F42B12/06,34,74; F42B30/02


(71) RUAG AMMOTEC

(72) Spatz, Peter; Baumgartner, Hans; Schaer, Fritz;

(31) 04 569876 (32) 11 May 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) A small-bore projectile (100) is disclosed. The projectile (100) is suitable for hard targets, may be manufactured economically, has high penetration performance and target accuracy and does not release heavy metals on firing or in the target area as it contains no lead in the core. The projectile jacket (5) is also intended not to splinter on a hard target. The projectile (100) has an ogival or conical front region (1), a cylindrical central part and a conically extending tail region. The outer jacket (5) is made of a copper/zinc alloy, the jacket (5) having a tip (1) and fully enclosing a hollow space. A hard core (4) within the hollow space (7) is made of steel or a sintered material and has an outwardly projecting conical rear face tapered to a point. A jacket core (8), also made of a copper/zinc alloy, has a front face that fits to the conical rear of the hard core (4). A single interior cylindrical hollow space (7) extends within the jacket core (8) from the front face down the majority of the jacket (5) length. The jacket core (8) has an interference fit inside the jacket (5).



(21) 551196 (22) 16 May 2005

(54) Compounds and compositions for delivering active agents

(86) PCT/US2005/017309 (87) WO2005/112633

(51) IPC2010.01:C07C229/00

(71) Emisphere Technologies, Inc.

(72) Gomez-Orellana, Maria Isabel; Gschneidner, David; Leone-Bay, Andrea; Moye-Sherman, Destardi; Pusztay, Stephen V; Rath, Parshuram; Tang, Pingwah; Weidner, John J; Song, Jianfeng;

(31) 04 571195 (32) 14 May 2004 (33) US

(31) 04 571194 (32) 14 May 2004 (33) US

(31) 04 571090 (32) 14 May 2004 (33) US

(31) 04 571093 (32) 14 May 2004 (33) US

(31) 04 571151 (32) 14 May 2004 (33) US

(31) 04 571144 (32) 14 May 2004

(33) US

(31) 04 571089 (32) 14 May 2004

(33) US

(31) 04 571092 (32) 14 May 2004

(33) US

(31) 04 571055 (32) 14 May 2004

(33) US

(31) 04 571315 (32) 14 May 2004

(33) US

(31) 04 576397 (32) 1 Jun 2004

(33) US

(31) 04 576105 (32) 1 Jun 2004

(33) US

(31) 04 576088 (32) 1 Jun 2004


(33) US

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a tertiary amide carboxylic acid of general formula (A).

Wherein R1 is - (CH2)m-R8, wherein m= 0 or 1, R2 - R6 are independently selected from hydrogen, hydroxyl, halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, C1-C4 alkoxy, and cyano, R7 is selected from C1-C10 alkyl, C2- C10 alkenyl, and C2 - C 10 alkynyl, R8 is selected from cyclopentyl, cyclohexyl and phenyl, wherein when R8 is a phenyl, m= 1 and R8 is optionally substituted with C1 - C4 alkyl, C1-C4 alkoxy, halogen or hydroxyl, or a combination thereof. Also disclosed is a composition comprising said acid with an active agent.

Divisional filed as 586703



(21) 551198 (22) 17 Jun 2005

(54) 1-Aza-bicyclo[3.3.1]nonanes

(86) PCT/EP2005/006566 (87) WO2005/123732

(51) IPC2010.01:A61K31/439; A61P25/00; C07D471/04


(71) Novartis AG

(72) Feuerbach, Dominik; Muller, Werner; Roy, Bernard Lucien; Troxler, Thomas J; Hurth, Konstanze; Frederiksen, Mathias;

(31) 04 581020 (32) 18 Jun 2004 (33) US

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is an aza-bicyclononane compound of formula I wherein A represents O or N(R1); R1 represents hydrogen, C1-C4alkyl, or CF3-, and wherein the rest of the substituents are disclosed in the specification. Also disclosed is the use of a compound of formula I for the manufacture of a medicament for the prevention and treatment of psychotic and neurodegenerative disorders or diseases or conditions in which alpha7 nAChR activation plays a role or is implicated.



(21) 551241 (22) 16 May 2005

(54) Aryl ketone compounds and compositions for delivering active agents

(86) PCT/US2005/017339 (87) WO05/117854

(51) IPC2010.01:C07C59/74

(71) Emisphere Technologies, Inc.

(72) Rath, Parshuram; Gomez-Orellana, Maria Isabel; Vuocolo, Edmund A (deceased);

(31) 04 571090 (32) 14 May 2004 (33) US


(31) 04 571092 (32) 14 May 2004 (33) US

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a composition comprising at least one biologically active agent and an aryl ketone compound of the formula I or a salt thereof,

wherein n is an integer from 1 to 9, and R^1 to R^5 are independently hydrogen, C1-6 alkyl C1-6 alkoxy, C2-6 alkenyl, halogen, hydroxyl, -NH-C(O)-CH₃, or -O-C₆H₅, or a salt thereof. The aryl ketone compound facilitates the delivery of the active agents.

Also disclosed are specific aryl ketone compounds.



(21) 551374 (22) 18 Apr 2005

(54) Clopidogrel naphthalenedisulfonate salt and polymorphic forms thereof

(86) PCT/US2005/013279 (87) WO2005/103059

(51) IPC2010.01:C07D495/04; A61K31/4365; A61P7/02

(71) SANOFI-AVENTIS

(72) Lorimer, Keith Richard; NG, Alicia Tee Fuay;

(31) 04 563795 (32) 20 Apr 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is methyl(+)-(S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-C]pyridine-5(4H) acetate naphthalene-1,5-disulfonate, (a clopidogrel salt) or a polymorphic form, hydrate, or solvate thereof. Also disclosed are six specific polymorphs of the above salt, or of a hydrate or solvate thereof. Also disclosed is the use of any of the above compounds to inhibit platelet aggregation or to reduce atherosclerotic events.

(21) 551447 (22) 18 May 2005

(54) Methods for dynamic vector assembly of DNA cloning vector plasmids

(86) PCT/US2005/017272 (87) WO2005/116231

(51) IPC2010.01:C07H21/04; C12N15/09,11,63; C12P19/34; C12N15/66

(71) Intrexon Corporation

(72) Reed, Thomas D;

(31) 04 572011 (32) 18 May 2004 (33) US

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, Melbourne, Victoria 3000, Australia

(57) Disclosed is a method of constructing a transgene or a method for simultaneously synthesizing an array of transgenes the method comprising the steps of:

a. providing a cloning vector plasmid with a backbone comprising first and second docking points capable of accepting a sequential arrangement of inserts, each docking point being fixed within the backbone and comprising at least one non-variable rare endonuclease site for an endonuclease enzyme;

b. providing at least a first insert and a second insert to be included in the transgene, each insert comprising a 5' end, a nucleotide sequence of interest and a 3' end, wherein the 5' end of the first insert is compatible to the 3' end of the cleaved first docking point, and the 3' end of the second insert is compatible to the 5' end of the cleaved second docking point; and

c. transferring both the first insert and the second insert into the backbone in a single reaction.

Further discloses is an alternative method of constructing a transgene or a method for simultaneously synthesizing an array of transgenes the method comprising the steps of:

a. providing a cloning vector plasmid comprising first and second docking points;

b. introducing first nucleotide sequences to be included in the transgene into a first shuttle vector;

c. introducing second nucleotide sequences to be included in the transgene into a second shuttle vector; and

d. transferring simultaneously the first nucleotide sequences and the second nucleotide sequences from the shuttle vectors to the cloning vector

plasmid, between the first and second docking points, wherein the 5' end of the first insert is compatible to the 3' end of the first docking point, and the 3' end of the second insert is compatible to the 5' end of the second docking point.

Divisional filed as 583974

(21) 551502 (22) 16 Jun 2005

(54) Adhesive composition, method for bonding to a metal surface and rubber to metal adhesive

(86) PCT/US2005/021520 (87) WO2006/007438

(51) IPC2010.01:C08K3/00; C09J11/04; C09J123/28

(71) LORD CORPORATION

(72) Green, Christian C; Tallmadge, Jack N;

(31) 04 580306 (32) 16 Jun 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is an adhesive composition having a pigment grind of 0-2 mils (0 to 0.05 mm) measured by the Hegman® guage, said adhesive is sprayable at a total solids concentration of 25 ± 2 wt.%, has a viscosity of from 50 to 500 cps (Brookfield LVT 2 @ 30 rpm) and comprises a nitroso compound, filmforming halogenated polyolefin, acid acceptor and from 5% to 35 dry wt.% of inert, incompressible, spheroidal particles having a BET surface area of from 0.1 to 10 m²/g and a 50th percentile particle diameter (D50) of 5 to 25 μ m. Also disclosed are a rubber-to-metal adhesive which comprises a plurality of microspheres wherein said adhesive having a weight percent concentration of at least one percent of the microspheres and a viscosity less than 500 cps (Brookfield LVT 2 @ 30 rpm), and a method for spray applying the rubber-to-metal adhesive composition which comprises spraying onto a metal surface in an amount to provide a dry film thickness of from 0.0003 to 0.002 inch (0.007 to 0.0508 mm) +/- 0.0001 to 0.0003 (0.0025 to 0.0076 mm) in one or two sprayed layers.

(21) 551516 (22) 20 May 2005

(54) A direct reduction process characterised by agglomeration of fine ore particles and increased retention time

(86) PCT/EP2005/005465 (87) WO2005/116274

(51) IPC2010.01:C21B13/00; C22B5/14


(71) Outotec Oyj

(72) Orth, Andreas; Eichberger, Heinz; Philp, Donald Keith; Dry, Rod;

(31) 04 902898 (32) 31 May 2004 (33) AU

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) A direct reduction process for a metalliferous feed material, particularly for an iron-containing feed material, such as iron ore is disclosed. The process involves supplying the metalliferous material, a solid carbonaceous material, oxygen containing gas, and a fluidising gas into a fluidised bed in a vessel. The fluidised bed is maintained in the vessel, metalliferous material is partially reduced and then a product stream comprising the partially reduced metalliferous material is discharged from the vessel. The distinguishing feature in this process is that it involves a combination of a carbon rich zone (17) and the introduction of an oxygen containing gas in this zone which is then applied to cause agglomeration of the fine ore particles and thereby increase their retention time.



(21) 551564 (22) 14 Jun 2005

(54) Providing freezing and thawing resistance to cementitious compositions

(86) PCT/EP2005/006331 (87) WO2005/123618

(51) IPC2010.01:C04B16/08; C04B28/02

(71) CONSTRUCTION RESEARCH & TECHNOLOGY GMBH

(72) Christensen, Bruce J; Vickers, Thomas M; Gay, Frank T;

(31) 04 579692 (32) 15 Jun 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) The disclosure relates to a freeze-thaw durability wet cast cementitious composition that uses microspheres that are blended directly into the wet cast cementitious composition. The microspheres provide voids in the wet cast cementitious composition material matrix, and such voids acts to increase freeze-thaw durability of the cured and hardened cementitious material. Particularly disclosed is a cementitious freeze-thaw damage resistant wet cast composition comprising hydraulic cement and polymeric microspheres, wherein the polymeric microspheres have an average diameter of about 0.1 micrometer to less than about 10 micrometers, and the polymeric microspheres are liquid filled. The polymer that is suitable for the polymeric microspheres may be selected from one of polyethylene, polypropylene, polymethyl methacrylate, poly-o-chlorostyrene, polyvinyl chloride, polyvinylidene chloride, polyacrylonitrile, polymethacrylonitrile, polystyrene, or copolymers or mixtures thereof.

(21) 551590 (22) 4 May 2005

(54) Midface distractor with a central adjustment assembly allowing adjustment in two degrees of freedom

(86) PCT/US2005/015592 (87) WO2005/107620

(51) IPC2010.01:A61B17/58,60,62,64,66


(71) SYNTHES GmbH

(72) Noon, John M; Ciccone, Paul C;

(31) 04 839551 (32) 4 May 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is a external midface distractor for attachment to the bones of a patient's cranium and midface region for performing an osteogenesis procedure to gradually lengthen a portion of the craniofacial skeleton. The midface distractor includes an external halo assembly for engaging the patient's cranium, a central adjustment assembly, a vertical central rod, at least one horizontal cross piece assembly including at least one distraction screw, and at least one bone engaging portion. The central adjustment assembly includes a front portion attached to the vertical central rod, the front portion being angularly adjustable in at least two degrees of freedom relative to a rear portion which is attached to the halo assembly. The midface distractor may thus provide surgeons with additional anterior-posterior and medial-lateral adjustments, permitting more precise and accurate control of the distraction vector.



(21) 551630 (22) 8 Jun 2005

(54) Quinazolinone derivatives useful as vanilloid antagonists

(86) PCT/EP2005/006253 (87) WO2005/120510

(51) IPC2010.01:A61K31/505; A61P11/06; A61P29/00; C07D239/88

(71) Novartis AG


(72) Ritchie, Timothy John; Culshaw, Andrew James; Brain, Christopher Thomas; Dziadulewicz, Edward Karol; Hart, Terance;

(31) 04 0412769 (32) 8 Jun 2004 (33) GB

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a quinazolinone compound of the formula (I) wherein the substituents are disclosed within the specification.

Also disclosed is the use of a quinazolinone compound in the manufacture of a medicament for the treatment or prevention of pain, inflammatory diseases, gastrointestinal disturbances or disorders, or diseases of the urogenital tract.



(21) 551645 (22) 21 Jun 2005

(54) Storage bag with a valve and a pressure sensitive adhesive in an inner surface to assist in elimination of air

(86) PCT/US2005/021747 (87) WO2006/012083

(51) IPC2010.01:B31B39/00; B65D30/08; B65D33/00,20


(71) THE PROCTER & GAMBLE COMPANY

(72) Hall, Bruce Neil; Singer, James Michael; Giesfeldt, Rebecca Sue; Cisek, Ronald Joseph;

(31) 04 880106 (32) 28 Jun 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A storage bag (10') is disclosed. The bag (10') allows for easy removal of air surrounding the any item in the bag (10'). The bag (10') has two opposing sidewalls (12', 14') which are attached to each other at the side and bottom (20'). At least one of the sidewalls has an outer layer (30') and an inner layer (32') which is substantially unattached to the outer layer except at its peripheral edges. The inner face (38') is covered in protrusions and valleys, the valleys at least partly filled with an adhesive. At least one sidewall has a valve which may be used to extract air from the bag (10'). The bag (10') may also have a closure at the open end (22).



(21) 551659 (22) 8 Jun 2005

(54) Novel CIS-imidazolines

(86) PCT/EP2005/006167 (87) WO2005/123691

(51) IPC2010.01:A61K31/415,454,496,5377; C07D233/22; C07D401/14; C07D403/06

(71) F.Hoffmann-La Roche AG


(72) Haley, Gregory Jay; Kong, Norman; Liu, Emily Aijun; VU, Binh Thanh;

(31) 04 580441 (32) 17 Jun 2004 (33) US

(31) 05 674196 (32) 22 Apr 2005 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of formula I, or a pharmaceutically acceptable salt or ester thereof, wherein R is an optionally substituted 5 or 6 membered heterocycle, and wherein the other substituents are as defined in the specification. Also disclosed is a process for preparing the above compound, and its use to treat diseases which are based on the interaction of MDM2 protein with a p53 like peptide, such as cancer and solid tumors.



(21) 551664 (22) 17 Jun 2005

(54) Alkynyl derivatives as modulators of metabotropic glutamate receptors

(86) PCT/IB2005/002390 (87) WO2005/123703

(51) IPC2010.01:A61K31/422,47,4709; C07D213/56; C07D215/06; C07D233/54; C07D239/26; C07D263/56; C07D277/22; C07D401/06; C07D403/06; C07D413/06; C07D417/06; C07D471/04; C07D498/04


(71) ADDEX PHARMA SA

(72) Bessis, Anne-Sophie; Bolea, Christelle; Bonnet, Beatrice; Poirier, Nicholas; Poli, Sonia-Maria; Rocher, Jean-Philippe; Thollon, Yves; Epping-Jordan, Mark;

(31) 04 0413605 (32) 17 Jun 2004 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) The disclosure relates to pyridine derivative compounds of formula (I) wherein W, X, R15, R16, R17, R18 and R19 are as defined in the specification, these compounds are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors. These compounds are particularly suitable for treating or preventing central nervous system disorders selected from the group consisting of: addiction, tolerance or dependence, affective disorders, psychiatric disease, Parkinson's disease, memory impairment, Alzheimer's disease, dementia, delirium tremens, other forms of neurodegeneration, neurotoxicity, and ischemia; for treating or preventing inflammatory or neuropathic pain; for treating or preventing behaviour disorders and dependence disorders selected from the group consisting of alcohol, nicotine, cocaine, amphetamine, benzodiazepine, analgesics, opiate or other substance tolerance or dependence, bulimia nervosa, anorexia nervosa, gambling dependence, sex dependence, or obsessive compulsive disorders; for treating or preventing schizophrenia, depression and attention-deficit/hyperactivity disorder; and such other disorders modulated by mGluR5 receptors.



(21) 551742 (22) 3 Jun 2005

(54) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

(86) PCT/US2005/019472 (87) WO2005/121147

(51) IPC2010.01:A61K31/53; C07D487/04; C07D519/00

(71) BAYER HEALTHCARE LLC

(72) Dixon, Julie A; Brennan, Catherine; Miranda, Karl; Chandler, Brent; Phillips, Barton; Fan, Jianmei; Brands, Michael; McClure, Andrea; Jones, Benjamin; Fu, Wenlang; Bierer, Donald; Magnuson, Steven; Kluender, Harold C E;

(31) 04 576652 (32) 3 Jun 2004 (33) US

(31) 04 626531 (32) 9 Nov 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) This disclosure to pyrrolotriazine compounds of formula (I), pharmaceutical compositions containing such compounds and the use of those compounds and compositions for the prevention and/or treatment of hyper-proliferative disorders and diseases associated with angiogenesis, particularly cancer, wherein the variables shown in formula (I) are as defined in the specification.

(21) 551834 (22) 1 Jun 2005

(54) Milking device with a thermoplastic flexible teat-receiving sleeve

(86) PCT/SE2005/000824 (87) WO2005/120217

(51) IPC2010.01:A01J5/08; B29D99/00


(71) DELAVAL HOLDING AB

(72) Pettersson, Torbjorn; Kassibrahim, Jan; Odeberg, Johan;



(31) 04 0401488 (32) 10 Jun 2004 (33) SE

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is a milking device which includes a teat-receiving flexible sleeve adapted to be positioned on or over a teat. The sleeve includes a first portion consisting of a thermoplastic elastomer as defined in ISO 18064, and a second portion consisting of a thermoplastic material. A method of manufacturing the milking device is also claimed.



- (21) 551845 (22) 7 Jun 2005
 (54) Cationic bacteriochlorophyll derivatives and uses thereof
 (86) PCT/IL2005/000602 (87) WO2005/120573
 (51) IPC2010.01:A61K31/409; A61K41/00; A61P35/00; C07D487/22
 (71) YEDA RESEARCH AND DEVELOPMENT CO. LTD.
 (72) Scherz, Avigdor; Brandis, Alexander; Salomon, Yoram; Eren, Doron; Cohen, Avraham;
 (31) 04 577196 (32) 7 Jun 2004 (33) US
 (74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
 (57) The disclosure relates to cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives of formula (I), (II) or (III) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions. These bacteriochlorophyll derivatives of formula (I), (II) or (III) are useful as a photosensitizer for photodynamic therapy and diagnosis of tumours.



- (21) 551887 (22) 11 Oct 2005
 (54) Organo-gel formulations for therapeutic applications
 (86) PCT/US2005/036064 (87) WO2006/042059
 (51) IPC2010.01:A61K31/74; A61K6/00; A61K9/00
 (71) Mediquest Therapeutics, Inc
 (72) Dechow, Frederick J;
 (31) 04 960516 (32) 8 Oct 2004 (33) US
 (31) 04 066485 (32) 28 Feb 2005 (33) US
 (31) 04 150254 (32) 13 Jun 2005 (33) US
 (74) FRASER OLD & SOHN, Level 10, The Bayer Building, 275 Alfred Street, North Sydney, NSW 2060, Australia
 (57) Disclosed is a composition comprising two biocompatible organic solvents, a polar lipid, at least one or more surfactant, wherein said surfactant comprises a docusate, 40-65 % by weight of water, urea and thickener; wherein the organic solvents comprise an ester and propylene glycol; and wherein the composition comprises 2 to 30% by weight of the ester and 0.5 to 20% by weight of the propylene glycol, and wherein said ester is an isopropyl ester of a fatty acid having 4 to 22 carbon atoms. Also disclosed is a method of making the above composition, and the use of the composition to deliver a medicament topically into and through the epidermis tissue, such as to treat skin or nail infections or diseases.
- (21) 551931 (22) 7 Jun 2005
 (54) Alcohol reduction in beverages
 (86) PCT/AU2005/000814 (87) WO2005/121306
 (51) IPC2010.01:C12H3/04
 (71) Memstar Pty Ltd
 (72) Wollan, David;
 (31) 04 903139 (32) 9 Jun 2004 (33) AU
 (31) 04 907247 (32) 21 Dec 2004 (33) AU
 (74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, Victoria, Australia
 (57) Disclosed is a method of reducing the alcohol content of an alcohol containing beverage involving the steps of:
 (i) processing the beverage by reverse osmosis or nanofiltration for producing a retentate and a raw permeate which includes alcohol;
 (ii) contacting a first side of a hydrophobic microporous membrane with said raw permeate;
 (iii) contacting a second side of the membrane with a strip solution to extract alcohol therefrom to form a dealcoholised permeate; and
 (iv) combining the retentate with the dealcoholised permeate to form a dealcoholised beverage which has an alcohol content lower than that of the beverage.
 Also disclosed is an apparatus for performing the above method, and a dealcoholised beverage produced by the method.

- (21) 551951 (22) 25 May 2005
 (54) Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
 (86) PCT/US2005/018381 (87) WO2005/117910
 (51) IPC2010.01:A61K31/70
 (71) Inotek Pharmaceuticals Corporation
 (72) Jagtap, Prakash; Szabo, Csaba; Salzman, Andrew L;

(31) 04 574805 (32) 26 May 2004 (33) US
(31) 04 588263 (32) 15 Jul 2004 (33) US
(74) INOTEK NEW ZEALAND LTD, Level 6, St. John House, 114 The Terrace, Wellington, New Zealand

(57) The disclosure relates to purine derivatives, compositions comprising an effective amount of a purine derivative; and their use for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, or wasting disease, or diabetes.

(21) 551955 (22) 6 Jun 2005
(54) Methods and compositions for treating ophthalmic conditions with retinyl derivatives

(86) PCT/US2005/020080 (87) WO2006/007314

(51) IPC2010.01:A61K31/167; A61P27/02

(71) ReVision Therapeutics, Inc.

(72) Widder, Kenneth; Lichter, Jay; Mata, Nathan L;

(31) 04 582293 (32) 23 Jun 2004 (33) US


(31) 04 629695 (32) 19 Nov 2004 (33) US

(31) 05 660904 (32) 11 Mar 2005 (33) US

(31) 05 672405 (32) 18 Apr 2005 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is the use of the pictured compound, wherein X1 is NR2, O, S, CHR2, R1 is (CHR2)x-L1-R3, x is 0-3, and the other substituents are as defined in the specification, to reduce the formation of N-retinylidene-N--retinylethanolamine or lipofuscin, to treat macular degeneration, or to reduce geographic atrophy, in the eye.



(21) 551956 (22) 9 Jun 2005

(54) Seals made of a multi-layered material for sealing means, particularly a sealing capsule

(86) PCT/FR2005/001426 (87) WO2006/000706

(51) IPC2010.01:B32B27/06; B32B5/18; B65D53/04


(71) ALCAN PACKAGING CAPSULES

(72) Granger, Jacques;

(31) 04 0406336 (32) 11 Jun 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A seal particularly for a wine bottle screw cap includes a compressible base layer C of an expanded polyolefin, a support layer S and an oxygen barrier layer B on the support layer S. The layer B can be between the layers C and S, or the layer S can be between the layers C and B. In either case the layer B or the layer S are intended to be in contact with the wine in the bottle.



(21) 552003 (22) 14 Jun 2005

(54) Screen assembly designed to conform to the radius of vibrating shakers with crowned decks

(86) PCT/US2005/020729 (87) WO2006/002023

(51) IPC2010.01:B07B1/49,46


(71) M-I L.L.C.

(72) Barrett, Robert M; Carr, Brian S;

(31) 10 868206 (32) 15 Jun 2004 (33) US

(74) COLLISON & CO, 117 King William Street, Adelaide, South Australia 5001, Australia

(57) A screen for attachment to the crowned deck of a vibrating shaker includes a frame 1 with an underside 17 that is non-planar and a screen mesh 16 attached to the top side. When the screen is attached to the crowned deck it flexes so that the shape of the underside of the frame matches the non-planar profile of the crowned deck.



(21) 552036 (22) 25 Aug 2005

(54) Novel compounds having an anti-bacterial activity

(86) PCT/EP2005/009204 (87) WO2006/021448

(51) IPC2010.01:A61K31/445; A61P31/04; C07D401/14; C07D405/14; C07D417/14; C07D419/14

(71) MORPHOCHEM AKTIENGESELLSCHAFT FÜR KOMBINATORISCHE CHEMIE

(72) Pierau, Sabine; Dale, Glenn; Cappi, Michael W; Zumbrunn, Cornelia; Hubschwerlen, Christian; Surivet, Jean-Philippe;


(31) 04 04041163 (32) 25 Aug 2004 (33) DE

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) The disclosure relates to anti-bacterial naphthyridin derivative compounds of formula (I)

Q-NH-CO-R3

wherein Q is a group having the structure shown herein and the variables R1, X1, X2, X3, X4, X5 & X6 are as defined in the specification. These compounds are inhibitors of DNA gyrase and are suitable for treating bacterial infections.



(21) 552056 (22) 16 Jun 2005

(54) Sulfamate and sulfamide derivatives for the treatment of epilepsy and related disorders

(86) PCT/US2005/021513 (87) WO2006/007435

(51) IPC2010.01:A61K31/353,357; A61P25/08; C07D311/58; C07D317/58; C07D319/20; C07D321/08


(71) JANSSEN PHARMACEUTICA N.V.

(72) Mccomsey, David F; Parker, Michael N; Reitz, Alen B; Maryanoff, Bruce E;

(31) 04580178 (32) 16 Jun 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) The disclosure relates to sulfamide and sulfamate derivatives represented by formula (II) and pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification; pharmaceutical compositions containing them and their use in the treatment of epilepsy and related disorders.



(21) 552187 (22) 20 Jun 2005

(54) Thiophene-2-carboxamide derivatives

(86) PCT/US2005/021817 (87) WO2006/002099

(51) IPC2010.01:A61K31/381; C07D333/38; A61P9/00


(71) Millennium Pharmaceuticals, Inc

(72) Zhu, Bing-Yan; Bauer, Shawn M; Jia, Zhaozhong J; Probst, Gary D; Zhang, Yanchen; Scarborough, Robert M;

(31) 04 580899 (32) 18 Jun 2004 (33) US

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed are thiophene-2-carboxamide derivatives as represented by the general formula (I), or a pharmaceutically acceptable salt thereof wherein, A represents an optionally substituted benzene, a six-membered heterocycle or heteroaryl containing 1-3 nitrogen atoms or a five-membered heterocycle or heteroaryl containing 1-4 nitrogen, oxygen or sulphur atoms; R is hydrogen or alkyl; R1 is halogen, alkyl, alkenyl or alkynyl; R2 is H, alkyl, -X-OR2a, -X-SR2a, -X-COR2a, -X-CO2R2a, or -X-N(OR2a)2; W is an optionally substituted phenyl, pyridyl or piperidinyl moiety; and wherein the remaining substituents are as defined herein. Also disclosed is a composition comprising a pharmaceutically acceptable excipient and a compound as defined above. Further disclosed is the use of a therapeutically effective amount of a compound as defined above in the production of a medicament for preventing or treating a condition in a mammal characterized by undesired thrombosis (conditions such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, occlusive coronary thrombus occurring post-thrombolytic therapy or post-coronary angioplasty, a thrombotically mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, transient ischemic attacks, venous thrombosis, deep vein thrombosis, pulmonary embolus, coagulopathy, disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, thromboangiitis obliterans, thrombotic disease associated with heparin-induced thrombocytopenia, thrombotic complications associated with extracorporeal circulation, thrombotic complications associated with instrumentation such as cardiac or other intravascular catheterisation, intra-aortic balloon pump, coronary stent or cardiac valve, and conditions requiring the fitting of prosthetic devices).



(21) 552220 (22) 9 Jun 2005

(54) Preparation of pregabalin and related compounds

(86) PCT/IB2005/001924 (87) WO2006/000904

(51) IPC2010.01:C07C227/18; C07C253/30; C07C255/03; C07D207/04

(71) WARNER-LAMBERT COMPANY


(72) Hu, Shanguai; Martinez, Carlos Alberto; Tao, Junhua; Tully, William Eugene; Kelleher, Patrick Gerard Thomas;

(31) 04 581671 (32) 21 Jun 2004 (33) US

(31) 04 629034 (32) 18 Nov 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a method of making a compound of Formula 1, or a pharmaceutically acceptable complex, salt, solvate or hydrate thereof, in which R1 and R2 are different and are each independently selected from hydrogen atom, C1-12 alkyl, C3-12 cycloalkyl, and substituted C3-12 cycloalkyl, the method comprising: (a) reacting a compound of Formula 2, or a salt thereof, with an acid and water to yield the compound of Formula 1 or a salt thereof; and (b) optionally converting the compound of Formula 1 or a salt thereof into a pharmaceutically acceptable complex, salt, solvate or hydrate, wherein R1 and R2 in Formula 2 are as defined for Formula 1. Also disclosed are intermediates.



(21) 552225 (22) 16 Jun 2005

(54) Sound modulating laminate for floor tiles

(86) PCT/US2005/021390 (87) WO2006/007413

(51) IPC2010.01:B32B21/08; E04F15/04

(71) SEALED AIR CORPORATION (US); CRYOVAC, INC


(72) Grah, Michael D; Rivett, Janet;

(31) 04 869283 (32) 16 Jun 2004 (33) US

(31) 05 091161 (32) 28 Mar 2005 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) A sound proofing flooring laminate 10 comprises a core layer 12 with one or more acoustic layers 14 adhered to the core layer. The core layer 12 has a maximum thickness of 30 mils and is made from one or more materials selected from wood and wood composite. The total maximum thickness of the acoustic layers is greater than 5 mils. Each acoustic layer 14 has a maximum thickness of 60 mils and is made from one or more polymers selected from acrylonitrile/chloroprene copolymer, acrylonitrile/isoprene copolymer, butadiene/acrylonitrile copolymer, chlorinated polyethylene, chlorosulfonated polyethylene, ethylene ether polysulfide, ethylene polysulfide, ethylene/propylene copolymer, ethylene/propylene/diene terpolymer, fluoroelastomer, fluorosilicone, hexafluoropropylene/vinylidene fluoride copolymer, isobutene/isoprene copolymer, organopolysiloxane, acrylic ester/butadiene copolymer, polybutadiene, polychloroprene, polyepichlorohydrin, polyisobutene, polyisoprene, polyurethane, polyethylene-butyl graft copolymer, styrenic copolymer, ethylene/unsaturated ester copolymer, ethylene/(meth)acrylic acid copolymer and ethylene/alpha-olefin copolymer. Each acoustic layer 14 has an average density of about 0.912 g/cc, a maximum glass transition temperature of 0°C, a maximum crystallinity of 39 % by weight and is essentially non-foamlike.



(21) 552249 (22) 9 Jun 2005

(54) Dry-forming three-dimensional wood fiber webs

(86) PCT/US2005/020634 (87) WO2006/002015

(51) IPC2010.01:B29C43/04


(71) JOHN S. FUJII

(72) Fujii, John S;

(31) 04 580282 (32) 15 Jun 2004 (33) US

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) The three dimensional mould into which a flat dry-formed mat of wood fibres is deep drawn so as to mould the mat into a three dimensional wood fibre structural core is provided with fillets and curved corners (not illustrated) adjacent the laminating platforms 2, 6 and load bearing diagonal elements 1, 5, 4. This facilitates fibre draw during the moulding process at the intersection of the laminating platforms and load bearing diagonal elements and prevents tearing of the mat.



(21) 552341 (22) 4 Jul 2005

(54) Film packaging a number of objects in a row to be removed individually by breaking perforations in the film

(86) PCT/JP2005/012349 (87) WO2006/004094

(51) IPC2010.01:B65D71/08; B65B61/12


(71) Kabushiki Kaisha Yakult Honsha; Toho Shoji Kabushiki Kaisha

(72) Goto, Yoshihiro; Teramoto, Takayoshi; Terada, Takayuki;

(31) 04 199103 (32) 6 Jul 2004 (33) JP

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) A package is disclosed (OP). The package (OP) contains a plurality of objects (DG) having a shoulder and a vertically long and cylindrical shape which are arranged in a horizontal line and wrapped. The wrapping material (PM) is perforated to enable ease of removing a single object (DG) from the package. A plurality of perforated lines (MM) cross a gap between the shoulders of the objects (DG) and extend in a line in the horizontal direction across each shoulder.



(21) 552368 (22) 27 Jun 2005

(54) Mandrel assembly for manufacturing tubular products using a first plate with a drive roller and at least one idler roller

(86) PCT/AU2005/000937 (87) WO2006/000051

(51) IPC2010.01:B29C53/58,82; F16L11/16; F16L9/16

(71) Nova-Duct Technologies Pty Ltd

(72) Donnelly, William James;

(31) 2004 903473 (32) 25 Jun 2004 (33) AU

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, Melbourne, Victoria 3000, Australia

(57) A mandrel assembly 130 for manufacturing a tubular product comprises a circular base 206, a cantilever drive roller 202 extending from the base 206, other cantilever rollers 204 also extending from the base 206 and a motor 218 that rotates the cantilever drive roller 202. When the mandrel assembly 130 is used a strip of material engages with the cantilever drive roller 202 and is wound around the other cantilever rollers 204 to form a tubular product. The mandrel assembly 130 can turn 252 about an axis parallel to the plane of the base 206 so that the other cantilever rollers 204 remain at right angles to the movement of the strip as it is engaged by the cantilever drive roller 202 and wound about the cantilever rollers with a helical movement.

(21) 552388 (22) 14 Jul 2005

(54) A system for directing cooling air onto a neck ring in a glassware molding machine

(86) PCT/US2005/025069 (87) WO2006/019964

(51) IPC2010.01:C03B9/38

(71) OWENS-BROCKWAY GLASS CONTAINER INC.

(72) Flynn, Robin L;

(31) 04 892677 (32) 15 Jul 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a system for directing cooling air onto a neck ring in a glassware molding machine. The glassware molding machine is of the type including a stationary blank mold station with a plunger cylinder having an axis; a neck ring arm selectively aligned with the blank mold station, and at least one neck ring carried by the neck ring arm and movable into a forming position which is coaxially aligned with the axis. The system for directing cooling air includes at least one air plenum disposed at the blank mold station. The air plenum has an internal cavity for receiving cooling air flowing laterally inwardly toward the axis, and has at least one outlet opening adjacent the axis. The system also includes a plunger wear plate which overlays a portion of the air plenum. The plunger wear plate has an array of axially oriented openings for receiving air directed from the air plenum. The system further includes a number of openings in the neck ring arm for receiving air from the openings in the plunger wear plate and a number of air passages in the neck ring for receiving air from the neck ring arm openings.

Divisional filed as 586403

(21) 552398 (22) 20 Jul 2005

(54) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors for treatment of diabetes

(86) PCT/EP2005/007894 (87) WO2006/010546

(51) IPC2010.01:A61K31/435; A61P3/00; C07D213/76; C07D401/12

(71) F.Hoffmann-La Roche AG

(72) Amrein, Kurt; Hunziker, Daniel; Kuhn, Bernd; Mayweg, Alexander; Neidhart, Werner;

(31) 04 04103639 (32) 28 Jul 2004 (33) EP

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Aryl-pyridine derivatives having the structure of formula (I) for use as 11-beta-HSD1 inhibitors to treatment of diabetes, diabetes Type II, obesity, eating disorder, dyslipidemiae and hypertension, wherein:


R1 is hydrogen, alkyl, cycloalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, amino or aminoalkyl;

R2 is hydrogen, alkyl or halogen;


R3 is hydrogen, alkyl or halogen;

R4 is phenyl, naphthyl, thiophenyl, pyridyl, quinolyl, piperidyl, morpholyl or thiomorpholyl optionally substituted with one or more substituents independently selected from alkyl, cycloalkyl, halogen, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, hydroxyalkoxy, alkoxyalkoxy, cyano, trifluoromethyl, trifluoromethoxy, aryl, arylalkyl, aryloxy, heterocyclyl, alkylcarbonylamino, alkoxycarbonylalkoxy and alkyl-SO₂-;

R5 is hydrogen or alkyl;
R6, R7, R8, R9 and R10 are independently selected from hydrogen, alkyl, halogen, cyano, trifluoromethyl, alkoxy and alkyl-SO₂-;
A is nitrogen or C-R10;
E is nitrogen or C-R9
G is nitrogen or C-R8;
Wherein not more than one of A, E and G is nitrogen; and pharmaceutically acceptable salts and esters thereof.




(21) 552484 (22) 23 Jun 2005
(54) Custom mouthguard
(86) PCT/US2005/022418 (87) WO06/012278
(51) IPC2010.01:A61C5/14
(71) EDWARD J. AMBIS, JR.
(72) Ambis, Edward J;
(31) 04 876501 (32) 25 Jun 2004 (33) US
(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand
(57) A comfortable moulded mouthguard that contains the upper jaw teeth and provides mutual stability to the upper jaw teeth, the lower jaw teeth that interact with the mouthguard and the lower jaw. The mouthguard will also allow open mouth breathing and speaking. The mouthguard comprises of an upward facing V-shaped trough, with the trough having a bottom and anterior and posterior walls. The inner surface of the posterior wall has a palatal seal (post dam) next to the upper edge of the posterior wall. The mouthguard is moulded to conform to the shape of the upper jaw teeth and the adjoining palatal and gum tissue. The bottom of the mouthguard is shaped so that when the mouth is closed, the bottom of the mouthguard conforms to the shape of the crowns of the teeth in the lower jaw and restricts the movement of the lower jaw teeth in all directions except away from the mouthguard.




(21) 552542 (22) 29 Jun 2005
(54) Azaindoles useful as inhibitors of protein kinases
(86) PCT/US2005/023429 (87) WO2006/004984
(51) IPC2010.01:A61K31/437, 4745; A61P35/00; C07D471/04
(71) Vertex Pharmaceuticals Incorporated
(72) Pierard, Francoise; Jimenez, Juan-Miguel; Kengtel, Ronald; Brenchley, Guy; Mortimore, Michael; Mazzei, Francesca;

(31) 04 584383 (32) 30 Jun 2004 (33) US
(31) 04 584721 (32) 1 Jul 2004 (33) US
(31) 05 98751 (32) 4 Apr 2005 (33) US
(31) 05US 0511358 (32) 4 Apr 2005 (33) US
(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, Australia
(57) Disclosed are azaindoles compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined in the specification, and their use as inhibitors of protein kinases such as the Tec family and for treating diseases such as asthma, acute rhinitis and AIDS.




(21) 552622 (22) 30 Jun 2005
(54) Herbicidal Compositions
(86) PCT/EP2005/007041 (87) WO2006/007947
(51) IPC2010.01:A01N43/68
(71) Bayer CropScience AG
(72) Hacker, Erwin; Rose, Eckhard; Dietrich, Hansjorg;
(31) 04 04034571 (32) 17 Jul 2004 (33) DE
(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand
(57) Disclosed a herbicide combination comprising an effective amount of components (A) and (B), where component (A) is one or more herbicides of the formula (I) or salts thereof, wherein the substituents are as defined in the specification and component (B) is one or more herbicides (B) which are structurally different from the herbicides (A) present in each case, selected from the group of compounds consisting of:
(B1) soil-acting herbicides particularly suitable for pre-emergence application against monocotyledonous or dicotyledonous harmful plants,
(B2) foliar-acting herbicides particularly suitable for post-emergence application against monocotyledonous or dicotyledonous harmful plants, and
(B3) soil-acting and foliar-acting herbicides suitable for pre- or post-emergence application against monocotyledonous or dicotyledonous harmful plants.



(21) 552630 (22) 22 Jul 2005
(54) Controller, system and method for providing supplementing water
(86) PCT/AU2005/001096 (87) WO2006/007669
(51) IPC2010.01:E03B1/04; E03C1/02; F16K11/04; F16K31/122, 126; G05D7/01
(71) DAVEY PRODUCTS PTY. LTD.
(72) Brown, Rodney James; Zhang, Da-Wei;
(31) 04 904071 (32) 22 Jul 2004 (33) AU
(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, Victoria 3000, Australia
(57) A supplementing water supply controller is disclosed. The controller includes: a housing defining: a first flow passage having an inlet con-

nectable to a main water supply; a second flow passage having an inlet connectable to a supplementing water supply at a pressure less than the pressure of the main water supply; an outlet for each flow passage connectable to a water supply conduit; and a chamber; and an actuator mounted for movement in the chamber by two diaphragms. One diaphragm is associated with a first end of the actuator and a second diaphragm is associated with a second opposite end of the actuator. In use, the first end of the actuator with its associated diaphragm and the second opposite end of the actuator with its associated diaphragm are, respectively, exposed to different pressures within the housing. The second opposite end of the actuator and its associated diaphragm being exposed to pressure prevailing at the inlet to the second flow passage which pressure will be relatively lower than the pressure prevailing on the first end of the actuator with its associated diaphragm due to the supplementing water supply pressure being less than the pressure of the main water supply. The actuator at its first end with its associated diaphragm is moveable to prevent flow along the first flow passage by causing a seal to be formed against a valve seat defined by the housing. A surface area of the actuator and its associated diaphragm at the second opposite end that is exposed to the pressure of the supplementing water supply exceeds a surface area of the actuator and its associated diaphragm at the first end that is exposed to the different pressure within the housing such that on supply of supplementing water below the pressure of the main water supply but above a threshold pressure. The actuator is moveable to prevent flow along the first flow passage.



(21) 552646 (22) 28 Jul 2005

(54) Method and device for the transfer of heat from a heat source to a thermodynamic cycle with a working medium of at least two substances with non-isothermal evaporation and condensation

(86) PCT/EP2005/053690 (87) WO2006/013186

(51) IPC2010.01:F01K25/06


(71) SIEMENS AKTIENGESSELLSCHAFT

(72) Blonn, Jann; Lengert, Jorg; Ruhland, Kathrin;

(31) 04 37417 (32) 30 Jul 2004 (33) DE

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Heat from a high temperature heat source 2 is transferred to a thermodynamic cycle 9 where the thermodynamic cycle 9 has a working medium composed of at least two substances with non-isothermal evaporation and condensation characteristics and the temperature of the high temperature heat source 2 is more than the decomposition temperature of the working medium of the thermodynamic cycle 9. Heat from the high temperature heat source 2 is transferred to an intermediate hot liquid cycle 4 through a first heat exchanger 3. The temperature of the working medium in the hot liquid cycle 4 is at about the boiling temperature of the working medium in the thermodynamic cycle 9. Heat is then transferred from the hot liquid cycle 4 to the thermodynamic cycle 9 through a second heat exchanger 5.



(21) 552666 (22) 19 Apr 2005

(54) Cationic Polymers Containing 2-Hydroxyethyl-methacrylate As Promoters For ASA Sizing

(86) PCT/US2005/013334 (87) WO2006/007001

(51) IPC2010.01:C08F220/28,36,56; C08F226/02; D21H17/37

(71) KEMIRA OYJ

(72) Pawlowska, Lucyna; Proverb, Robert;

(31) 04 580556 (32) 17 Jun 2004 (33) US

(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, Australia

(57) The disclosure relates to cationic polymers or amphoteric polymers having a 2-hydroxyethyl methacrylate ranging from 1 to 30 mole percent, as defined in the specification, which are useful as papermaking additives for enhancing the sizing efficiency of a paper product. The disclosure also relates to methods for making and using such additives in making paper products.

(21) 552692 (22) 20 Jul 2005

(54) Use of apoptosis-specific EIF-5A sirnas for the manufacture of a medicament for use in the treatment of a disease treatable by suppression of the JAK/STAT pathway.

(86) PCT/US2005/025766 (87) WO2006/014752

(51) IPC2010.01:A61P11/00; A61K31/713; C12N15/113

(71) Senesco Technologies, Inc.

(72) Thompson, John E; Galton, Bruce C; Dinarello, Charles; Boone, Adrienne; Taylor, Catherine; Reznikov, Leonid; Hopkins, Marianne;

(31) 04 589073 (32) 20 Jul 2004 (33) US

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is the use of an siRNA of an apoptosis specific eIF-5A in the manufacture of a medicament for use in the treatment of a condition treatable by suppression of the activation of the JAAK/STAT pathway, wherein said siRNA suppresses activation of the JAK/STAT pathway in a cell.

(21) 552765 (22) 27 Jun 2005

(54) A method using Pheromones

(86) PCT/GB2005/002504 (87) WO2006/000798

(51) IPC2010.01:A01N37/02; C07C69/14,145,24

(71) East Malling Research Limited; University of Greenwich

(72) Cross, Jeremy Vincent; Hall, David Robert;

(31) 04 14359 (32) 25 Jun 2004 (33) GB

(31) 04 23294 (32) 20 Oct 2004 (33) GB

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is a method to disrupt the mating patterns of, or detect the presence of a midge using a pheromone substance. The pheromone substance is a C9-19 oxoalkyl or oxoalkenyl molecule substituted with a

C1-6 alkanoyloxy group. The alkanoyloxy group or the oxo group is located at the 2-position. Also disclosed is an apparatus used to perform the method and a pheromone substance having the structure of formula I.



(21) 552847 (22) 27 Jul 2005

(54) Smelting apparatus including a solids injection lance extending through a side wall of the vessel

(86) PCT/AU2005/001101 (87) WO2006/010208

(51) IPC2010.01:C21B11/00; C21B13/00; C21C5/30,32,34,35; F27D3/06,16,18


(71) Technological Resources Pty Limited

(72) Hayton, Mark;

(31) 04 904199 (32) 27 Jul 2004 (33) AU

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, Hamilton, New Zealand

(57) Smelting apparatus comprises a converter 11, a solid material injection lance 31 that extends downwards and inwards through the side wall of the converter 11, a track 40 that extends upwards and outwards from the side wall of the converter, carriages 42 44 with a carriage drive 46 that move the carriages 42 44 along the track 40. The carriages 42 44 can be connected to the lance 31, so that the lance 31 is supported by and moved along the track 40 thus allowing the lance 31 to be inserted into or extracted from the converter 11.



(21) 552921 (22) 29 Jun 2005

(54) Gypsum plasterboard comprising at least a covering paper with a coating slip comprising plastic pigments, coating slip and related manufacturing method

(86) PCT/FR2005/001646 (87) WO2006/010853

(51) IPC2010.01:D21H19/42; E04C2/04

(71) LAFARGE PLATRES

(72) Hedman, Goran Erik;

(31) 04 0407272 (32) 30 Jun 2004 (33) FR

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand

(57) Disclosed is plasterboard comprising at least one facing paper forming the exterior of the plasterboard and a coating slip deposited on said facing paper, characterised in that the coating slip contains plastic pigments as whitening agents.

Also disclosed are a manufacturing process for said plasterboard and the use of a coating slip comprising plastic pigments to form the exterior of said plasterboard.

(21) 552924 (22) 2 Aug 2005

(54) N-(1H-indolyl)-1H-indole-2-carboxamide derivatives, their preparation and their therapeutic use

(86) PCT/FR2005/002014 (87) WO2006/024776

(51) IPC2010.01:A61K31/404; A61P29/00; C07D209/42


(71) sanofi-aventis

(72) Dubois, Laurent; Evanno, Yannick; Even, Luc;

(31) 04 0408652 (32) 5 Aug 2004 (33) FR

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is an indole derivative of formula (I), or an acid addition salt, hydrate, solvate thereof, wherein the substituents are as defined in the specification. Also disclosed is a process for preparing the above compound, and the use of the compound to treat pathologies which involve receptors of TRPV1, such as pain, inflammation, urological disorders, gynaecological disorders, gastrointestinal disorders, respiratory disorders, psoriasis, pruritus, irritation of the skin, eyes, or mucous membranes, herpes, shingles, or depression.



(21) 553077 (22) 25 Jul 2005

(54) Using geothermal energy for the production of power

(86) PCT/IL2005/000794 (87) WO2006/027770

(51) IPC2010.01:F03G7/00; F24J3/00,08

(71) Ormat Technologies Inc.

(72) Bronicki, Lucien Y;

(31) 04 910613 (32) 4 Aug 2004 (33) US

(74) J.D. Hardie & Co, 14th Floor, 48 Emily Place, Auckland, New Zealand

(57) A method for recovering geothermal heat is disclosed. The method includes enhancing the flow of geothermal fluid from at least one injection well to at least one production well. Water is injected into a horizontal injection well, and geothermal fluid is recovered from a horizontal production well. The production well is substantially horizontally and vertically spaced from the injection well, and is at a shallower depth. The method then includes generating a water density difference and a pressure difference between the injection well and the production well, extracting heat from the geothermal fluid recovered from the production well and using the heat for the production of energy.

(21) 553085 (22) 23 Aug 2005

(54) Methanesulfonate salts of abiraterone-3-esters and recovery of salts of abiraterone-3-esters from solution in methyl tert-butyl ether

(86) PCT/GB2005/003282 (87) WO2006/021776

(51) IPC2010.01:C07J31/00; C07J43/00

(71) BTG INTERNATIONAL LIMITED


(72) Hunt, Neil John;

(31) 04 0418900 (32) 24 Aug 2004 (33) GB

(31) 04 603559 (32) 24 Aug 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is the methanesulfonic acid salt of an abiraterone derivative as represented by the formula (I), where R' represents a lower acyl group having 2 to 4 carbon atoms and R represents a hydrogen atom or an alkyl group of 1-4 carbon atoms. Also disclosed is a process for the preparation of a compound as defined above or a pharmaceutically acceptable salt thereof, which includes the step of recovering an acid addition salt of the compound from methyl tert-butyl ether (MTBE).



(21) 553148 (22) 31 Aug 2005

(54) Benzamide compounds as inhibitors of the enzyme histone deacetylase

(86) PCT/GB2005/003355 (87) WO2006/024841

(51) IPC2010.01:A61K31/4418,4427,4439,444,4545,496,497,506; C07D213/85; C07D401/06,12,14; C07D405/12; C07D417/12; C07D487/08

(71) ASTRAZENECA AB

(72) Gibson, Keith Hopkinson; Stokes, Elaine Sophie Elizabeth; Waring, Michael James; Andrews, David Michael; Graham, Mark Andrew; Matusiak, Zbigniew Stanley;


(31) 04 0419565 (32) 3 Sep 2004 (33) GB

(31) 05 0502545 (32) 8 Feb 2005 (33) GB

(31) 05 0506165 (32) 29 Mar 2005 (33) GB

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) The disclosure relates to benzamide compounds of formula (I) that are inhibitors of the enzyme histone deacetylase, wherein the variables shown in formula (I) have the meanings as defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours or other proliferative conditions which are sensitive to the inhibition of histone deacetylase (HDAC).



(21) 553160 (22) 31 Aug 2005

(54) Anilino-substituted triazolophthalazine derivatives having PDE2 inhibitory activity

(86) PCT/EP2005/054266 (87) WO2006/024640

(51) IPC2010.01:A61K31/5025; C07D487/04

(71) Nycomed GmbH


(72) Schmidt, Beate; Weinbrenner, Steffen; Flockerzi, Dieter; Kuelzer, Raimund; Tenor, Hermann; Kley, Hans-Peter;

(31) 04 04104221 (32) 2 Sep 2004 (33) EP

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed are anilino-substituted triazolophthalazine derivatives of formula (I), wherein the variables are as defined in the specification. Pharmaceutical composition comprising these triazolophthalazine derivatives are therapeutically effective for antagonizing the effects of the cyclic nucleotide phosphodiesterase of type 2 (PDE2), ameliorating the symptoms of an PDE2-mediated disorder, and are useful for preventing or treating PDE2-mediated disorders particularly for treating (1) conditions associated with pathologically enhanced neoangiogenesis such as

all kinds of tumors (benign or malignant) or (2) all kinds of inflammatory diseases associated with neoangiogenesis such as disorders of the arthritis type.



(21) 553181 (22) 12 Aug 2005

(54) Counter mechanism of feeder and feeder having counter mechanism

(86) PCT/JP2005/015112 (87) WO2006/016726

(51) IPC2010.01:A61M13/00; A61M15/00


(71) Teijin Pharma Limited

(72) Mochizuki, Seiji; Kawada, Dai; Tsuji, Yoshitaka; Ogino, Shigeto; Toyonaga, Hitoshi; Henmi, Hirofumi; Yamano, Masatake;

(31) 04 235415 (32) 12 Aug 2004 (33) JP

(74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, Victoria, Australia

(57) A counter mechanism of a feeder for feeding a stored material stored in a storage chamber to the outside in increments of single feed amount for each rotating operation capable of detecting the residual amount of the stored material in invisible devices by counting the number of times of feeding of the stored material by a simple structure. The counter mechanism comprises a fixed member (10) fixed to a feeder body and having a cam part at a specified position in the circumferential direction, a gear (20) having a count number indicator visible from the outside, a rotating member (40) rotatably restricted so as to be positioned in the rotating direction to allow the feeding of the stored material by a single feed amount and positioned in the rotating direction to stop the feeding of the stored material, and a ring member (30) rotatable in association with the rotating member and having an elastically deformable cam follower part having a claw at a specified position in the circumferential direction. The claw is engaged with the gear by a cam action between the cam part and the cam follower part while the rotating member is rotated for a single feed amount to rotate the gear by only one scale on the count number indicator.



(21) 553245 (22) 16 Sep 2005

(54) Slow closure mechanism for toilet covers

(86) PCT/IB2005/053049 (87) WO2006/035338

(51) IPC2010.01:A47K13/12


(71) ECZACIBASI YAPI GERECLERI SANAYI VE TICARET A.S.

(72) Er, Osman; Ileriye Pelin;

(31) 04 0402481 (32) 28 Sep 2004 (33) TR

(74) McCABE & COMPANY, Level 6, Polo House, 267 Wakefield Street, Wellington, New Zealand

(57) The subject of the disclosure is a slow closure mechanism (A) for toilet covers wherein it comprises two-hinge bodies (1), two pins (2), two dampers (3) and a body cover (4). Slow closing and easy opening process of toilet covers are achieved by tightly recessing the pins (2) and dampers (3) in the hinge body (1), connecting toilet covers and body cover (4) to pin shaft and damper shaft in slow closure mechanism (A).



(21) 553322 (22) 2 Sep 2005

(54) Fumarate of 4-(4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, also named TMC278

(86) PCT/EP2005/054341 (87) WO2006/024667

(51) IPC2010.01:A61K31/505; A61P31/18

(71) JANSSEN PHARMACEUTICA N.V.

(72) Vandecruys, Roger Petrus Gerebern; Stappers, Alfred Elisabeth; Copmans, Alex Herman; Stevens, Paul Theodoor Agnes; Peeters, Jozef;


(31) 04 20043578 (32) 2 Sep 2004 (33) MY

(31) 04EP 04052028 (32) 3 Sep 2004 (33) EP

(31) 05 05101447 (32) 25 Feb 2005 (33) EP

(74) BALDWIN'S INTELLECTUAL PROPERTY, Level 14, Baldwin's Centre, 342 Lambton Quay, Wellington 6011, New Zealand

(57) Disclosed is the fumarate salt of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile, also known as TMC278. The compound is useful for the treatment of HIV infections.



(21) 553406 (22) 27 Jul 2005

(54) Nucleoside phosphonate conjugates as anti-HIV agents

(86) PCT/US2005/027088 (87) WO2006/015261

(51) IPC2010.01:A61K31/662


(71) GILEAD SCIENCES, INC.

(72) Booramra, Constantine G; Lin, Kuei-Ying; Mackman, Richard L; Markevitch, David Y; Petrakovsky, Oleg V; Ray, Adrian S; Zhang, Lijun;

(31) 04 591811 (32) 27 Jul 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound as depicted in the formula, or a pharmaceutically acceptable salt or solvate thereof and its use for inhibiting HIV.



(21) 553468 (22) 14 Sep 2005

(54) 4-((phenoxymethyl)thio)-phenoxycetic acids and analogs

(86) PCT/US2005/032938 (87) WO2006/031969

(51) IPC2010.01:A61K31/185; C07C323/10,20,62; C07C59/68

(71) JANSSEN PHARMACEUTICA N.V.


(72) Deangelis, Alan; Demarest, Keith T; Kuo, Gee-Hong; Pelton, Patricia; Wang, Aihua; Zhang, Rui;

(31) 04 609967 (32) 15 Sep 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of Formula (I) wherein X is selected from a covalent bond, S and O; Y is S or O; Z is O of CH₂, provided when Y is O then Z is O; and wherein the rest of the substituents are disclosed within the specification; or a pharmaceutically acceptable salt thereof.

Also disclosed is the use of a compound of Formula (I) in the preparation of a medicament for treating or inhibiting the progression of a PPAR-delta mediated condition.



(21) 553469 (22) 14 Sep 2005

(54) 4-((phenoxymethyl)thio)-phenoxycetic acids and analogs

(86) PCT/US2005/033137 (87) WO2006/032023

(51) IPC2010.01:A61K31/185; C07C323/10,20,62; C07C59/68

(71) JANSSEN PHARMACEUTICA N.V.

(72) Deangelis, Alan; Demarest, Keith T; Kuo, Gee-Hong; Pelton, Patricia; Wang, Aihua; Zhang, Rui;

(31) 04 609942 (32) 15 Sep 2004 (33) US

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, Wellington 6011, New Zealand

(57) Disclosed is a compound of Formula (I) wherein X is selected from a covalent bond, S or O; Y is S or O; Z is selected from O, CH and CH₂ provided when Y is O, Z is O; and wherein the rest of the substituents are disclosed within the specification; or a pharmaceutically acceptable salt thereof. Also disclosed is the use of a compound of Formula (I) in the preparation of a medicament for treating or inhibiting the progression of a PPAR-delta mediated condition.

